"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT01998126","Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer",,"Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Ipilimumab|Drug: Erlotinib|Drug: Crizotinib|Drug: Nivolumab","toxicity of ipilimumab and erlotinib in EGFR mutated patients|toxicity of ipilimumab and crizotinib in ALK mutated patients|toxicity of nivolumab and erlotinib in EGFR mutated patients|toxicity of nivolumab and crizotinib in ALK mutated patients|Response rate|Progression Free Survival (PFS)|Overall Survival|immune function pre and post immune therapy","University of Utah|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI66705","December 2, 2013","May 9, 2017","March 29, 2018","November 28, 2013",,"April 2, 2018","Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01998126"
2,"NCT03287674","TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer",,"Active, not recruiting","No Results Available","Metastatic Ovarian Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL infusion|Drug: Interleukin-2|Drug: Ipilimumab|Drug: Nivolumab","Number and type of reported adverse events|Treatment related immune responses|Objective response rate|Overall Survival|Progression free survival","Inge Marie Svane|Herlev Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GY1721","October 9, 2017","October 2022","October 2023","September 19, 2017",,"February 12, 2020","Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03287674"
3,"NCT03841110","FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors|Lymphoma|Gastric Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|EGFR Positive Solid Tumor|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer|Melanoma|NSCLC|Urothelial Carcinoma|Cervical Cancer|Microsatellite Instability|Merkel Cell Carcinoma","Drug: FT500|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Atezolizumab|Drug: Cyclophosphamide|Drug: Fludarabine","The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.|Objective-response rate (ORR)|Duration of FT500 persistence","Fate Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FT500-101","February 15, 2019","March 2022","June 2022","February 15, 2019",,"September 27, 2019","UCSD Moores Cancer Center, San Diego, California, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03841110"
4,"NCT04038619","Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients",,"Not yet recruiting","No Results Available","Colitis|Diarrhea|Malignant Genitourinary System Neoplasm","Procedure: Fecal Microbiota Transplantation|Drug: Loperamide","Incidence of fecal microbiota transplantation (FMT)-related adverse events|Clinical response/remission of immune-related diarrhea/colitis|Recurrent immune-related diarrhea/colitis within 3 months post-FMT after initially achieving clinical remission/response","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0663|NCI-2019-02660|P30CA016672","March 2, 2020","July 31, 2021","July 31, 2021","July 31, 2019",,"February 28, 2020","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04038619"
5,"NCT03388632","Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers",,"Recruiting","No Results Available","Metastatic Solid Tumors|Treatment-Refractory Cancers","Drug: rhIL-15|Drug: Ipilimumab|Drug: Nivolumab","Safety, toxicity profile, dose-limiting toxicity (DLT), and maximumtolerated doses (MTD)|Response rate|Biological effects","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180033|18-C-0033","February 5, 2018","September 1, 2021","September 1, 2021","January 3, 2018",,"April 20, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03388632"
6,"NCT04009681","A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors","THOR-707-101","Recruiting","No Results Available","Solid Tumor, Unspecified, Adult","Drug: THOR-707|Drug: Checkpoint inhibitor","Rate of Dose-Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose|Objective Response Rate (ORR) according to RECIST version 1.1|Duration of Response (DOR) according to RECIST version 1.1|Progression-Free Survival (PFS) according to RECIST version 1.1|Overall Survival according to RECIST version 1.1|Time to Response (TTR) according to RECIST version 1.1|Disease Control Rate (DCR) according to RECIST version 1.1|Immunophenotyping of peripheral blood at various timepoints|Immunophenotyping of tumor samples at various timepoints|Assess presence of antibodies to THOR-707 at various timepoints|Assess plasma concentration of THOR-707 at various timepoints","Synthorx, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","THOR-707-101","June 20, 2019","June 2022","June 2022","July 5, 2019",,"March 17, 2020","Synthorx Investigational Site, Denver, Colorado, United States|Synthorx Investigational Site, Sarasota, Florida, United States|Synthorx Investigational Site, Nashville, Tennessee, United States|Synthorx Investigational Site, Houston, Texas, United States|Synthorx Investigational Site, San Antonio, Texas, United States|Synthorx Investigational Site, Melbourne, Australia|Synthorx Investigational Site, Perth, Australia|Synthorx Investigational Site, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04009681"
7,"NCT03945253","Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors",,"Active, not recruiting","No Results Available","Advanced Solid Tumors","Drug: ASP8374","Safety and tolerability assessed by Dose Limiting Toxicity (DLT)|Safety and tolerability assessed by adverse events (AEs)|Safety and tolerability assessed by immune-related AEs (irAEs)|Safety and tolerability assessed by serious adverse events (SAEs)|Number of participants with laboratory value abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by 12-lead electrocardiogram (ECG)|Number of participants with vital signs abnormalities and/or adverse events related to treatment|Number of participants with physical exam abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by eastern cooperative oncology group (ECOG) performance status|Pharmacokinetics (PK) of ASP8374 in serum: AUClast|PK of ASP8374 in serum: AUCinf|PK of ASP8374 in serum: AUCinf(%extrap)|PK of ASP8374 in serum: AUCtau|PK of ASP8374 in serum: Cmax|PK of ASP8374 in serum: Ctrough|PK of ASP8374 in serum: tmax|PK of ASP8374 in serum: t1/2|PK of ASP8374 in serum: tlast|PK of ASP8374 in serum: CL|PK of ASP8374 in serum: Vz|PK of ASP8374 in serum: Vss|Percent change in tumor size from baseline|Best overall response (BOR) per RECIST 1.1 and 'immune' Response Evaluation Criteria in Solid Tumors (iRECIST)","Astellas Pharma Inc","All","20 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8374-CL-0102","August 5, 2019","December 2022","December 2022","May 10, 2019",,"March 12, 2020","Site JP81001, Chuo-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03945253"
8,"NCT03511222","Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors",,"Recruiting","No Results Available","Solid Tumor|Hepatocellular Carcinoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma","Drug: Vorolanib|Drug: Nivolumab|Drug: Pembrolizumab","Recommended phase II dose (RP2D) of vorolanib plus pembrolizumab|Recommended phase II dose (RP2D) of vorolanib plus nivolumab|Safety and toxicity of vorolanib plus pembrolizumab as measured by the number and type of adverse events experienced by participant|Safety and toxicity of vorolanib plus nivolumab as measured by the number and type of adverse events experienced by participant","Washington University School of Medicine|Xcovery Holding Company, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201806087","September 11, 2018","August 15, 2019","August 31, 2020","April 27, 2018",,"January 28, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03511222"
9,"NCT03453164","Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)",,"Recruiting","No Results Available","Gastric Cancer","Radiation: Radiotherapy + Nivolumab","Disease control rate|Median survival time|Incidence of treatment-emergent adverse events|Local control rate|Expression of PD-L1 and MHC class I on tumor cells, number of CD8 positive lymphocytes in tumor microenvironment|Peak plasma cytokine concentration|Peak regulatory T-cell population|Peak antigen-specific cytotoxic T lymphocyte population","Fukushima Medical University|Kanagawa Cancer Center","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RK29040","March 28, 2018","August 31, 2020","February 28, 2021","March 5, 2018",,"January 18, 2020","Fukushima Medical University Hospital, Fukushima, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03453164/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03453164"
10,"NCT03260322","A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors","Drug: ASP8374|Drug: Pembrolizumab","Safety and tolerability assessed by Dose Limiting Toxicity (DLT)|Safety and tolerability assessed by adverse events (AEs)|Safety and tolerability assessed by immune-related AEs (irAEs)|Safety and tolerability assessed by serious adverse events (SAEs)|Number of participants with laboratory value abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by 12-lead electrocardiogram (ECG)|Number of participants with vital signs abnormalities and/or adverse events related to treatment|Number of participants with Physical Exam abnormalities and/or adverse events related to treatment|Safety and tolerability assessed by ECOG performance status|Pharmacokinetics (PK) of ASP8374 in serum: AUClast (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: AUCinf (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: AUCtau (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: Cmax (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: Ctrough (Initial treatment, escalation and expansion cohorts in both monotherapy and combination therapy)|Pharmacokinetics (PK) of pembrolizumab in serum: Ctrough (Initial treatment, escalation cohorts in combination therapy)|Pharmacokinetics (PK) of ASP8374 in serum: Ctrough (Re-treatment, escalation and expansion cohorts in both monotherapy and combination therapy)|Pharmacokinetics (PK) of ASP8374 in serum: tmax (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: t1/2 (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: CL (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: Vz (Initial treatment, escalation cohorts in monotherapy only)|Pharmacokinetics (PK) of ASP8374 in serum: Vss (Initial treatment, escalation cohorts in monotherapy only)|Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST|Duration of response (DOR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST|Persistance of response after discontinuation by iRECIST|Disease control rate (DCR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST","Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8374-CL-0101|2018-001146-34","September 8, 2017","July 2021","April 2022","August 24, 2017",,"May 5, 2020","Honor Health Research Institute, Scottsdale, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|University Hospital of Cleveland, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Research Center, Dallas, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Site CA15004, Edmonton, Alberta, Canada|Site CA15003, Toronto, Ontario, Canada|Site CA15001, Toronto, Ontario, Canada|Site CA15002, Montreal, Quebec, Canada|Site IT39004, Ancona, Italy|Site IT39012, Meldola, Italy|Site IT39002, Milano, Italy|Site IT39003, Milano, Italy|Site IT39008, Milano, Italy|Site IT39009, Milano, Italy|Site IT39010, Modena, Italy|Site IT39005, Monza, Italy|Site IT39011, Negrar, Italy|Site IT39013, Pisa, Italy|Site IT39007, Siena, Italy|Site JP81001, Chuo-ku, Japan|Site KR82004, Goyang-si, Gyeonggi-do, Korea, Republic of|Site KR82005, Seongnam-Si, Gyeonggi-do, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|SIte KR82002, Seoul, Korea, Republic of|Site KR82006, Seoul, Korea, Republic of|Site PT35101, Lisboa, Portugal|Site PT35106, Porto, Portugal|Site ES34002, Barcelona, Spain|Site ES34003, Barcelona, Spain|Site ES34009, Barcelona, Spain|Site ES34010, Barcelona, Spain|Site ES34001, Madrid, Spain|Site ES34006, Madrid, Spain|Site ES34013, Madrid, Spain|Site ES34014, Valencia, Spain|Site TW88602, Taichung, Taiwan|Site TW88601, Tainan, Taiwan|Site TW88603, Taipei City, Taiwan|Site GB44001, Leeds, United Kingdom|Site GB44003, London, United Kingdom|Site GB44006, London, United Kingdom|Site GB44004, Newcastle upon Tyne, United Kingdom|Site GB44005, Sutton Surry, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03260322"
11,"NCT04243499","First-in-Human Study of ICT01 in Patients With Advanced Cancer","EVICTION","Recruiting","No Results Available","Solid Tumor, Adult|Hematopoietic/Lymphoid Cancer","Biological: IV ICT01","Adverse Events (Parts 1 & 2)|Objective Response Rate using RECIST for solid tumor patients (Part 2)|Objective Response Rate using RECIL for lymphoma patients (Part 2)|Change from Baseline in the Number of Circulating Gamma Delta T Cells|Change from Baseline in the Activation State of Circulating Gamma Delta T Cells|Cmax following the first dose of ICT01|AUC following the first dose of ICT01|Clearance at steady-state of ICT01|Half-life of ICT01|Objective Response Rate using iRECIST for solid tumor patients (Part 2)","ImCheck Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICT01-101","February 10, 2020","December 2022","December 2022","January 28, 2020",,"February 12, 2020","Institut Jules Bordet, Brussels, Belgium|Institut Goustave Roussey, Paris, France",,"https://ClinicalTrials.gov/show/NCT04243499"
12,"NCT04214418","Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","MEKiAUTO","Not yet recruiting","No Results Available","Gastrointestinal Cancer","Drug: Cobimetinib|Drug: Hydroxychloroquine|Drug: Atezolizumab","Phase 1: Estimated maximum tolerated dose (MTD)|Phase 1: Incidence of Treatment-Emergent Adverse Events with drug combination (Safety and Tolerability)","Columbia University|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","175","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAS4165|ML41472","March 2020","September 2022","September 2023","January 2, 2020",,"March 2, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04214418"
13,"NCT02467361","A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers",,"Active, not recruiting","No Results Available","Cancer","Drug: BBI608|Drug: Ipilimumab|Drug: Nivolumab|Drug: Pembrolizumab","Determination of the safety and tolerability of BBI608 administered in combination with selected immunotherapeutic agent by assessing dose-limiting toxicities (DLTs)|Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs)|Assessment of the preliminary anti-tumor activity by performing tumor assessments every 8 weeks (Phase 2 portion)|Pharmacokinetic profile of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by maximum plasma concentration and area under the curve|Pharmacodynamic activity of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by biomarker analysis","Boston Biomedical, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","104","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BBI608-201CIT","August 2015","June 2020","July 2020","June 10, 2015",,"January 21, 2020","University of Colorado Cancer Center, Denver, Colorado, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Institute for Translational Oncology Research, Greenville, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02467361"
14,"NCT03311334","A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors",,"Recruiting","No Results Available","Neoplasms|Melanoma|Non Small Cell Lung Cancer (NSCLC)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Renal Cell Carcinoma (RCC)|Urothelial Neoplasm|Hepatocellular Carcinoma (HCC)|Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR)|Colorectal Cancer|Gastroesophageal Junction Adenocarcinoma|Gastric Cancer|Cervical Cancer|Primary Peritoneal Cancer|Platinum-resistant Ovarian Cancer (PROC)|Serous Epithelial Ovarian Cancer|Fallopian Tube Cancer","Drug: DSP-7888 Dosing Emulsion|Drug: Nivolumab|Drug: Pembrolizumab","Phase Ib: Determination of the safety and tolerability of DSP-7888 Dosing Emulsion given intradermally with a checkpoint inhibitor (Nivolumab or Pembrolizumab) in adult patients with advanced solid tumors by assessing dose-limiting toxicities (DLTs).|Phase Ib: Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs).|Phase II: Evaluation of the preliminary antitumor activity of DSP-7888 Dosing Emulsion administered with pembrolizumab in terms of Objective Response Rate (ORR) in patients with platinum-resistant ovarian cancer (PROC).|Phase Ib: Objective response rate (ORR)|Phase Ib: Disease control rate (DCR)|Phase Ib: Duration of response (DOR)|Phase Ib: Progression-free survival (PFS)|Phase Ib: 6-month PFS|Phase Ib: Overall survival (OS)|Phase II: DOR|Phase II: DCR|Phase II: PFS|Phase II: 6 month PFS|Phase II: OS|Phase II: Immune objective response rate (iORR)|Phase II: Immune disease control rate (iDCR)|Phase II: Immune progression-free survival (iPFS)|Phase II: Evaluation of the safety and tolerability of DSP-7888 Dosing Emulsion administered with pembrolizumab.","Boston Biomedical, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","84","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BBI-DSP7888-102CI","December 14, 2017","November 2021","May 2022","October 17, 2017",,"January 22, 2020","Decatur Memorial Hospital, Decatur, Illinois, United States|Horizon Oncology Research, Lafayette, Indiana, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|UC Health, LLC, Cincinnati, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03311334"
15,"NCT03775850","A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",,"Recruiting","No Results Available","Colorectal Cancer Metastatic|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Bladder Cancer|GastroEsophageal Cancer|Renal Cell Carcinoma|MSI-H","Biological: EDP1503|Biological: Pembrolizumab","Safety and tolerability of EDP1503 alone and in combination with pembrolizumab as assessed per CTCAE v5.0|Safety and tolerability of EDP1503 alone and in combination with pembrolizumab|Evidence of anti-tumor activity of EDP1503 based on ORR|Progression Free Survival|Overall Survival","Evelo Biosciences, Inc.|SCRI Development Innovations, LLC|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDP1503-101","December 19, 2018","December 19, 2020","December 19, 2020","December 14, 2018",,"May 27, 2020","Highlands Oncology Group, Rogers, Arkansas, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Centre de Recherche du CHUM, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Canada",,"https://ClinicalTrials.gov/show/NCT03775850"
16,"NCT02852655","A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",,"Active, not recruiting","No Results Available","Brain Cancer","Drug: MK-3475","Tumor Infiltrating T Lymphocyte (TIL) Density|Incidence of Treatment-Emergent Adverse Events|Progression Free Survival","Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-225","September 21, 2016","March 28, 2018","August 2021","August 2, 2016",,"September 24, 2019","University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer, New York, New York, United States|UT, MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02852655"
17,"NCT04327986","Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer",,"Not yet recruiting","No Results Available","Histologically or Cytologically Confirmed Pancreatic Cancer|Unresectable or Borderline Resectable Pancreatic Cancer|Pancreatic Neoplasms|Pancreatic Cancer|Metastatic Pancreatic Cancer","Drug: M7824|Drug: M9241|Radiation: SBRT","To determine a preliminary estimate of efficacy as best overall response (BOR) according to RECIST 1.1 of M7824 and M9241 in combination with SBRT as neoadjuvant/perioperative treatment in subjects with locally advanced pancreas cancer|To determine the safety and tolerability and the recommended phase 2 dose (RP2D) of M7824 and M9241 in combination with SBRT as neoadjuvant / perioperative treatment in subjects with pancreas cancer|To determine the PK of M7824 in combination with M9241|To assess overall survival (OS) in patients after completion of RT in combination with M9241 and M7824|To asses progression-free survival (PFS) for all participants|To asses progression-free survival (PFS) for participants who did not undergo surgical resection|To determine fraction of patients with LAPC who are able to undergo surgical resection after M7824 and M9241 in combination with SBRT treatment|For patients who underwent surgical resection after M7824 and M9241 in combination with SBRT treatment to determine time-to-recurrence of the disease|For patients who underwent surgical resection after M7824 and M9241 in combination with SBRT treatment to determine complete pathological response rate(s)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","52","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200074|20-C-0074","June 5, 2020","December 31, 2025","December 31, 2025","March 31, 2020",,"June 2, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04327986"
18,"NCT04046133","Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus","CORINTH","Not yet recruiting","No Results Available","Anal Cancer Stage III A|Anal Cancer Stage III B","Drug: Pembrolizumab","Safety and tolerability- 30 days post CRT|Safety and tolerability- 6 weeks post CRT|Safety and tolerability - 12 weeks post CRT|Safety and tolerability - 6 months post CRT|Safety and tolerability- 9 months post CRT|Safety and tolerability- 12 months post CRT|Adherence to protocol treatment|Recruitment|Retention|Study eligibility|Clinical response assessment - 3 months post CRT|Clinical response assessment - 6 months post CRT|Clinical response assessment - 12 months follow up|Imaging response - 3 months post CRT|Imaging response - 6 months post CRT|Imaging response - 12 months follow up|Patient reported outcome - up to 6 months post CRT|Patient reported outcome - 12 months follow up","Cardiff University","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPON 1529-16","November 1, 2019","November 30, 2022","November 30, 2022","August 6, 2019",,"August 6, 2019",,,"https://ClinicalTrials.gov/show/NCT04046133"
19,"NCT03735290","A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer","ILIAD","Recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck|Carcinoma, Non-Small-Cell Lung|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Non-small Cell Lung Cancer|Human Papilloma Virus","Biological: ilixadencel|Drug: Pembrolizumab","Frequency of adverse events (AEs) (Phase 1b)|Severity of adverse events (SAEs) (Phase 1b)|Number of Dose Limiting Toxicities (DLTs) (Phase 1b)|Number of subjects with clinically significant laboratory test abnormalities (Phase 1b)|Number of subjects with vital sign abnormalities (Phase 1b)|Antitumor Objective Response Rate (ORR) (Phase 2)|Antitumor Objective Response Rate (ORR) RECIST 1.1 (Phase 1b and Phase 2)|Antitumor Objective Response Rate (ORR) iRECIST (Phase 1b and Phase 2)|Clinical Benefit Rate (Phase 1b and Phase 2)|Number of circulating CD8 t-cell responses to tumor-specific or tumor-associated antigens (Phase 1b and Phase 2)|Duration of response (Phase 1b and Phase 2)|Time to Progression (TTP) (Phase 1b and Phase 2)|Progression-free Survival (PFS) (Phase 1b and Phase 2)|Overall Survival (OS) (Phase 1b and Phase 2)|Frequency of adverse events (AEs) (Phase 2)|Severity of adverse events (AEs) (Phase 2)|Number of Dose Limiting Toxicities (DLTs) (Phase 2)|Number of subjects with clinically significant laboratory test abnormalities (Phase 2)|Number of subjects with vital sign abnormalities (Phase 2)","Immunicum AB|PPD","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IM-202","January 14, 2019","December 2022","July 2023","November 8, 2018",,"December 20, 2019","Site 1010, Coral Gables, Florida, United States|Site 1006, Iowa City, Iowa, United States|Site 1011, Louisville, Kentucky, United States|Site 1001, Detroit, Michigan, United States|Site 1004, Chapel Hill, North Carolina, United States|Site 1009, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03735290"
20,"NCT02903914","Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",,"Recruiting","No Results Available","Metastatic Cancer|Solid Tumors|Colorectal Cancer (CRC)|Gastric Cancer|Head and Neck Cancer|Lung Cancer|Renal Cell Carcinoma (RCC)|Bladder Cancer|UC (Urothelial Cancer)|Mesothelioma","Drug: INCB001158|Drug: Pembrolizumab","Safety and Tolerability of INCB001158 as a single agent and in combination with Pembrolizumab: Incidence of Adverse Events|Recommended Phase 2 Dose (RP2D) of INCB001158|RP2D of INCB001158 with Pembrolizumab|Plasma pharmacokinetic (PK) profile of INCB001158 alone and in combination with Pembrolizumab|Anti-tumor Activity of INCB001158 as Monotherapy and in Combination with Pembrolizumab for patients with advanced/metastatic solid tumors","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","424","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 01158-101","September 14, 2016","August 28, 2020","August 28, 2020","September 16, 2016",,"February 27, 2020","University of South Alabama, Mobile, Alabama, United States|Honor Health/Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Georgetown, Washington, District of Columbia, United States|Johns Hopkins, Baltimore, Maryland, United States|BIDMC, Boston, Massachusetts, United States|DFCI, Boston, Massachusetts, United States|Henry Ford, Detroit, Michigan, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States|MD Anderson, Houston, Texas, United States|START, San Antonio, Texas, United States|Ospedale San Raffaele, Milan, Italy|Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy|NKI, Amsterdam, Netherlands|Radboudumc, Nijmegen, Netherlands|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|START Madrid-HM CIOCC, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02903914"
21,"NCT03257722","Pembrolizumab + Idelalisib for Lung Cancer Study","PIL","Recruiting","No Results Available","Non Small Cell Lung Cancer|Metastasis|Recurrence","Drug: Pembrolizumab|Drug: Idelalisib","Number of Participants With Dose-Limiting Toxicity (DLT) Events as Assessed by CTCAE v4.03|Dose-Finding Assessment for optimum dose of idelalisib in combination with pembrolizumab|Overall Response Rates (ORR) to combination therapy","Zhonglin Hao|Merck Sharp & Dohme Corp.|Gilead Sciences|Augusta University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCC-16053","September 26, 2017","August 2020","August 2021","August 22, 2017",,"September 29, 2017","Georgia Cancer Center at Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03257722"
22,"NCT03881488","Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies",,"Recruiting","No Results Available","Locally Advanced Solid Tumor|Metastatic Cancer","Drug: CTX-471","Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities|Dose(s) of CTX 471 to be examined in Part 2 and the recommended Phase 2 dose(s)|Maximum serum concentration (Cmax) of CTX-471|Area under the serum concentrations of CTX-471 versus time curve (AUC)|Half-life (t1/2) of serum concentrations of CTX-471|Development of anti-drug antibodies (ADAs) and/or neutralizing antibodies of CTX-471|Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Progression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Overall Survival (OS)","Compass Therapeutics|Iqvia Pty Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1","81","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTX-471-001","May 17, 2019","March 2021","July 2021","March 19, 2019",,"April 3, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mt Sinai, New York, New York, United States|Duke University School of Medicine, Durham, North Carolina, United States|Institute for Translational Oncology Research (ITOR), Greenville, South Carolina, United States|Mary Crowley Cancer Research, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03881488"
23,"NCT03990233","A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours",,"Recruiting","No Results Available","Solid Tumor, Adult","Drug: BI 765063|Drug: BI 754091","Step 1 (dose escalation Parts A and B): Number of patients with Dose-Limiting Toxicities (DLTs) during the first treatment cycle|Step 1 (dose escalation Parts A and B): Maximum Tolerated Dose (MTD) determination|Step 2 (expansion monotherapy and combination Part C): Number of patients with DLT-like events during the whole treatment|Step 1: Number of patients with DLT-like events during the whole treatment|Step 1 and 2: Incidence and severity of all Adverse Events (AEs), Serious AEs (SAEs), AEs of special interest (AESIs), Immune related AEs (irAEs)|Step 2: Objective Response Rate (ORR) defined as best response of Complete Response (CR) and Partial Response (PR) as per RECIST v 1.1 criteria|Step 1 and 2: Cmax determination|Step 1 and 2: AUC 0-tz determination|Step 1 and 2: Percentage and evolution of SIRPα receptor occupancy (RO) in blood at pre, on-treatment and after the end of treatment","OSE Immunotherapeutics|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 1","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1443-0001|2018-003830-34","April 16, 2019","December 31, 2022","December 31, 2022","June 18, 2019",,"June 28, 2019","Institut Jules Bordet, Brussels, Belgium|Institut Bergonie, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Léon Berard, Lyon, France|Institut Claudius Regaud, Toulouse, France|Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT03990233"
24,"NCT04407247","Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma",,"Not yet recruiting","No Results Available","Colitis|Lung Non-Small Cell Carcinoma|Malignant Genitourinary System Neoplasm|Malignant Solid Neoplasm|Melanoma","Biological: Infliximab|Biological: Vedolizumab","Clinical remission/response rate of immune-mediated colitis (IMC)|Treatment-related adverse events|Clinical remission/response rate of IMC|Complete weaning of corticosteroid|Recurrent immune-related diarrhea/colitis","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-0276|NCI-2019-04986|P30CA016672","June 30, 2020","December 31, 2021","December 31, 2021","May 29, 2020",,"May 29, 2020","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04407247"
25,"NCT03834662","A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies",,"Active, not recruiting","No Results Available","Malignant Solid Tumor","Drug: AVID200","Incidence of Treatment-Emergent Adverse Events","Formation Biologics","All","18 Years and older   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVID200-03","January 7, 2019","July 30, 2020","August 1, 2020","February 8, 2019",,"May 12, 2020","START Midwest Clinic, Grand Rapids, Michigan, United States|MD Anderson Cancer Center, Houston, Texas, United States|Princess Margaret Cancer Centre, Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT03834662"
26,"NCT04387084","Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy",,"Not yet recruiting","No Results Available","Advanced Malignant Skin Neoplasm|Metastatic Malignant Skin Neoplasm","Drug: Atezolizumab|Drug: Avelumab|Biological: Cemiplimab|Biological: Durvalumab|Biological: Nivolumab|Biological: Pembrolizumab|Other: Quality-of-Life Assessment|Other: Short-Term Fasting","Percentage of patients completely adhering to 3 cycles of short term fasting (STF) (9 days of fasting)|Percentage of patients who develop unacceptable fasting-related toxicity|Percentage of patients who can partially adhere to 3 cycles of STF (9 days of fasting)|Incidence of acceptable fasting related toxicity","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0S-20-1|NCI-2020-01590|P30CA014089","June 1, 2020","June 1, 2022","June 1, 2023","May 13, 2020",,"May 13, 2020","Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04387084"
27,"NCT04095273","Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",,"Recruiting","No Results Available","Advanced Solid Tumors","Drug: BAY1895344|Drug: Pembrolizumab","Incidence of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)|Severity of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)|Frequency of Dose limiting toxicities (DLTs) at each dose level during dose escalation of BAY1895344|Cmax of BAY1895344|AUC(0-12) of BAY1895344|Cmax,md of BAY1895344|AUC(0-12)md of BAY1895344|Incidence of Complete response (CR)|Incidence of partial response (PR)|Incidence of stable disease (SD)|Incidence of progressive disease (PD)|Objective Response Rate (ORR)|Disease control rate (DCR)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19741|2018-003420-36","September 30, 2019","September 13, 2022","October 20, 2022","September 19, 2019",,"May 20, 2020","Stanford University, Palo Alto, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Johns Hopkins Hospital/Health System, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Eberhard-Karls-Universität Tübingen, Tübingen, Baden-Württemberg, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Fundacion Jimenez Diaz (Clinica de la Concepcion), Madrid, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04095273"
28,"NCT03343613","A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors",,"Active, not recruiting","No Results Available","Solid Tumor|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer","Drug: LY3381916|Drug: LY3300054","Number of Participants with Dose Limiting Toxicities (DLTs)|Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3381916|PK: Area Under the Plasma Concentration Curve (AUC) of LY3381916|PK: Cmax of LY3381916 Administered in Combination with LY3300054|PK: AUC of LY3381916 Administered in Combination with LY3300054|PK: Cmax of LY3300054 Administered in Combination with LY3381916|PK: Minimum Plasma Concentration (Cmin) of LY3300054 Administered in Combination with LY3381916|Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR)|Time to Response (TTR)|Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR|Duration of Response (DOR)|Progression Free Survival (PFS)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1","175","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16786|I9L-MC-JZCA|2017-002693-39","November 17, 2017","February 7, 2020","May 7, 2020","November 17, 2017",,"March 4, 2020","IU Simon Cancer Center, Indianapolis, Indiana, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Institut Jules Bordet, Brussel, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Finsen Institute, Copenhagen, Denmark|Gustave Roussy, Villejuif Cedex, France|Azienda Ospedaliera San Gerardo, Monza, Milano, Italy|Azienda Ospedaliera Umberto I, Ancona, Italy|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Andalucia, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03343613"
29,"NCT02989714","Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",,"Active, not recruiting","Has Results","Renal Cell Carcinoma","Drug: Interleukin-2|Drug: Nivolumab","The Number of Patients With Grade 3 and Grade 4 Adverse Events of Interest|The Number of Patients That Respond to Treatment|The Number of Patients With Grade 3-5 Adverse Events of Interest|The Number of Patients Alive at 24 Months|Time to Progression","University of Michigan Rogel Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2016.103|HUM00120502","March 16, 2017","February 25, 2019","October 2020","December 12, 2016","March 9, 2020","March 9, 2020","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02989714/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02989714"
30,"NCT02678741","Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.",,"Active, not recruiting","No Results Available","Metastatic Melanoma","Drug: TLPLDC Vaccine","Graded Standard Local and Systemic Toxicities (using CTCAE graded toxicity scale) months|Tumor Response to Treatment Using Response Evaluation Criteria in Solid Tumors (RECIST) criteria","Cancer Insight, LLC|Elios Therapeutics, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20152397","February 2016","December 2020","December 2020","February 10, 2016",,"March 26, 2020","University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|John Wayne Cancer Institute/Providence Saint John's Health Center, Santa Monica, California, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Providence Regional Medical Center, Everett, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02678741"
31,"NCT04020185","Safety and Efficacy Study of IMSA101 in Refractory Malignancies",,"Recruiting","No Results Available","Solid Tumor, Adult","Drug: IMSA101|Drug: Immune checkpoint inhibitor (ICI)|Drug: Immuno-oncology (IO) therapy","Maximum Tolerated Dose|Pharmacokinetic Sampling (Ph I)|Anti-tumor Effects","ImmuneSensor Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","115","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMSA101-101","September 23, 2019","February 16, 2023","February 16, 2023","July 15, 2019",,"January 22, 2020","Honor Health, Scottsdale, Arizona, United States|Northwestern University, Chicago, Illinois, United States|UT Southwestern, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04020185"
32,"NCT03237572","Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer","Breast-48","Recruiting","No Results Available","Breast Cancer","Drug: Pembrolizumab|Device: High-intensity focused ultrasound (HIFU)","Change in tumor infiltrating lymphocytes|Adverse event profile of pembrolizumab and HIFU","Patrick Dillon, MD|University of Virginia","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19900","September 25, 2017","September 16, 2020","November 25, 2021","August 2, 2017",,"May 8, 2020","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03237572"
33,"NCT04261439","A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab",,"Recruiting","No Results Available","In Escalation: All Patients With Solid Tumors and Lymphoma|In Expansion: Melanoma","Drug: NIZ985 and Spartalizumab","To characterize safety and tolerability of NIZ985 as a single agent and in combination with Spartalizumab: Dose Limiting Toxcities (DLTs)|Incidence and severity of adverse events (AEs)|Incidence and severity of serious adverse events (SAEs)|To assess preliminary anti-tumor activity of the NIZ985 and Spartalizumab combination: Overall response Rate (ORR)|Best Overall Response (BOR)|Disease control Rate (DCR)|Progression Free Survival (PFS) (expansion group only)|Duration of Response (DOR) (expansion group only)|To characterize the pharmacokinetics (PK) of NIZ985 as a single agent and NIZ985 and Spartalizumab in combination","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","68","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNIZ985B12101","February 27, 2020","September 9, 2021","September 9, 2021","February 7, 2020",,"March 31, 2020","Novartis Investigative Site, Chuo ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT04261439"
34,"NCT03558139","A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer",,"Active, not recruiting","No Results Available","Solid Tumor|Ovarian Cancer","Drug: Hu5F9-G4|Drug: Avelumab","Dose-Limiting Toxicities|Objective Response Rate","Forty Seven, Inc.|Merck KGaA, Darmstadt, Germany","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5F9006","May 24, 2018","December 2019","May 2023","June 15, 2018",,"July 31, 2019","University of Chicago, Chicago, Illinois, United States|START Midwest, Grand Rapids, Michigan, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|UT Southwestern, Dallas, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03558139"
35,"NCT03734692","Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer",,"Recruiting","No Results Available","Ovarian Cancer Recurrent","Drug: Rintatolimod|Drug: Pembrolizumab|Drug: Cisplatin","Objective Response Rate (ORR)|Progression-Free Survival (PFS)|Change in number of CD8+ cells|Change in number of CD3+ cells","Robert Edwards|AIM ImmunoTech Inc.|Merck Sharp & Dohme Corp.|University of Pittsburgh","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCC 18-087","January 28, 2019","February 20, 2021","November 20, 2023","November 8, 2018",,"December 3, 2019","Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03734692"
36,"NCT03333824","Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer",,"Completed","No Results Available","Solid Tumours","Drug: CYP1A2 (caffeine)|Drug: CYP2C19 (omeprazole)|Drug: CYP3A (midazolam)|Drug: Kytril (granisetron)|Drug: Wee-1 kinase inhibitor AZD1775","Part A: Area under the plasma concentration-time curve from zero to infinity for cocktail parent compounds (midazolam, omeprazole and caffeine)|Part A: Area under the plasma concentration-time curve from time zero to the time ""t"" of the last quantifiable concentration for cocktail parent compounds (midazolam, omeprazole and caffeine)|Part A: maximum plasma drug concentration for cocktail parent compounds (midazolam, omeprazole and caffeine)|Part B: dECG intervals (QTcF) for absolute values and time-matched change from baseline|Time to reach maximum plasma concentration for cocktail parent compounds (midazolam, omeprazole and caffeine)|Terminal half-life for cocktail parent compounds (midazolam, omeprazole and caffeine)|Elimination rate constant for cocktail parent compounds (midazolam, omeprazole and caffeine)|Apparent clearance following oral administration for cocktail parent compounds (midazolam, omeprazole and caffeine)|Apparent volume of distribution for cocktail parent compounds (midazolam, omeprazole and caffeine)|Area under the plasma concentration-time curve from zero to infinity for cocktail metabolites|Area under the plasma concentration-time curve from time zero to the time ""t"" of the last quantifiable concentration for cocktail metabolites|Time to reach maximum plasma concentration for cocktail metabolites|Maximum plasma drug concentration for cocktail metabolites|Terminal half-life for cocktail metabolites|Elimination rate constant for cocktail metabolites|Day 1, Part B Only: Area under the plasma concentration-time curve from time zero to 12 hours for AZD1775|Day 1, Part B only: Time to reach maximum plasma concentration for AZD1775|Day 1, Part B only: Maximum plasma drug concentration for AZD1775|Day 3, Parts A & B: Area under the plasma concentration-time curve from time zero to 12 hours for AZD1775|Day 3, Parts A & B: Time to reach maximum plasma concentration for AZD1775|Day 3, Parts A & B: Maximum plasma drug concentration for AZD1775|Day 3, Parts A & B: Minimum plasma drug concentration for AZD1775|Day 3, Parts A & B: Average concentration over a dosing interval for AZD1775|Day 3, Parts A & B: Apparent clearance at steady state for AZD1775|Day 3, Parts A & B: Fluctuation index (FI) over a dosing interval for AZD1775|Part B only: Accumulation ratio for area under the plasma concentration-time curve from time zero to twelve hours for AZD1775|Part B only: Accumulation ratio for maximum plasma drug concentration for AZD1775|dECG intervals (heart rate, RR, PR, QRS, QTcB, QTcF and QT) for absolute values and time-matched change from baseline|Changes in dECG morphology|Area under the plasma concentration-time curve from time zero to infinity ratios in relation to parent compound|Maximum plasma drug concentration ratios in relation to parent compound","AstraZeneca|Quintiles, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D6014C00006","December 1, 2017","January 22, 2019","January 22, 2019","November 7, 2017",,"March 25, 2019","Research Site, Bingham Farms, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Providence, Rhode Island, United States|Research Site, Greenville, South Carolina, United States|Research Site, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03333824"
37,"NCT02805660","Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC",,"Active, not recruiting","No Results Available","Advanced Cancer","Drug: mocetinostat|Drug: durvalumab","Incidence of dose limiting toxicities|Number of patients experiencing tumor size reduction|Number of patients experiencing Adverse Events|Blood plasma MGCD0103 concentration|Blood plasma MEDI4736 concentration","Mirati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","119","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0103-020","May 2016","April 2019","July 2020","June 20, 2016",,"June 11, 2019","Southern Cancer Center, PC, Mobile, Alabama, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Woodlands Medical Specialists - Pensacola, Pensacola, Florida, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|NorthShore University Health System, Evanston, Illinois, United States|Unniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|Texas Oncology - Denton South, Denton, Texas, United States|Texas Oncology-Plano West, Plano, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Shenandoah Oncology - Winchester, Winchester, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02805660"
38,"NCT02599454","Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Stage I Non-Small Cell Lung Cancer","Drug: Atezolizumab|Radiation: Stereotactic Body Radiation Therapy","Maximum Tolerated Dose|Disease free survival (DFS), assessed by RECIST 1.1 and irRECIST|Overall response rate (ORR), assessed by RECIST 1.1","Karen Kelly|Genentech, Inc.|University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","774542|UCDCC#258|ML29955|NCI-2015-01796","February 2016","September 2020","September 2021","November 6, 2015",,"October 28, 2019","University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|David Grant United States Air Force Medical Center, Travis Air Force Base, California, United States",,"https://ClinicalTrials.gov/show/NCT02599454"
39,"NCT04180215","A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers",,"Recruiting","No Results Available","HPV-Related Squamous Cell Carcinoma","Drug: HB-201 intravenous administration|Drug: HB-201 intratumoral administration on first cycle, followed by HB-201 intravenous administration on subsequent cycles","Recommended Phase 2 Dose (RP2D) for IV administration|Recommended Phase 2 Dose (RP2D) for IT administration|Number of patients receiving IV HB-201 experiencing treatment-emergent adverse events.|Number of patients receiving IT HB-201 experiencing treatment-emergent adverse events|Number of patients receiving IV HB-201 with tumor response throughout the study using RECIST v1.1 and/or iRECIST|Number of patients receiving IT HB-201 with tumor response throughout the study using RECIST v1.1 and/or iRECIST|Characterization of preliminary immunogenic properties of IV administration by intracellular staining and ELISpot assay.|Characterization of preliminary immunogenic properties of IT administration","Hookipa Biotech","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-200-001|2019-000907-34","December 11, 2019","January 2022","June 2022","November 27, 2019",,"May 7, 2020","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Henry Ford Hospital, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Montefiore-Einstein Center for Cancer Care, Bronx, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Greenville Hospital System University Medical Center (ITOR), Greenville, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04180215"
40,"NCT04029181","ImmunoPET With an Anti-CD8 Imaging Agent",,"Recruiting","No Results Available","Metastatic Cancer|Unresectable Malignant Neoplasm","Other: Anti-CD8 PET imaging agent","Incidence of adverse events related to tracer administration as assessed by CTCAE v4.0|Appropriate dosing of anti-CD8 imaging agent and PET imaging time points|Pharmacokinetics (PK) of anti-CD8 imaging agent|Immunogenic potential of the anti-CD8 imaging agent by measuring incidence of anti-drug antibodies|Heterogeneity of tumor uptake of the anti-CD8 imaging agent|Correlation of normal organ uptake of the anti-CD8 imaging agent to (serious) adverse events (possibly) related to immune checkpoint inhibitor treatment|Correlation of tumor uptake of the anti-CD8 imaging agent and immune cell CD8 expression|Correlation of anti-CD8 imaging agent normal tissue kinetics with blood kinetics|Dosimetry","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201700848","February 14, 2019","February 2021","February 2021","July 23, 2019",,"July 23, 2019","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04029181"
41,"NCT02460367","Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Non-small Cell Lung Cancer|Progression of Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Recurrent","Drug: Docetaxel|Biological: Tergenpumatucel-L|Drug: Indoximod","Regimen Limiting Toxicity|Progression Free Survival (PFS)|Frequency and grade of adverse events of tergenpumatuucel-L, indoximod and docetaxel|Objective Response Rate|Overall Survival|Response rate to subsequent therapy","NewLink Genetics Corporation|Lumos Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG0401|1504-1393","January 2016","July 17, 2017","August 1, 2032","June 2, 2015",,"May 28, 2020","Washington University in St. Louis, Saint Louis, Missouri, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02460367"
42,"NCT02777710","Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers","MEDIPLEX","Completed","No Results Available","Colorectal Cancer|Pancreatic Cancer|Metastatic Cancer|Advanced Cancer","Drug: Pexidartinib|Drug: Durvalumab","part 1 (dose escalation part) : Dose-Limiting Toxicities (DLT)|part 2 (extension part) : objective response rate (ORR)|The duration of response (DoR)|Progression-Free Survival (PFS)|Adverse events reporting|Area under the Pexidartinib plasma concentration (AUC) versus time curve|Peak Pexidartinib plasma concentration (Cmax)","Centre Leon Berard|AstraZeneca|Plexxikon","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET15-037 (MEDIPLEX)|2015-002438-31","June 2016","November 2019","December 2019","May 19, 2016",,"February 5, 2020","Centre Léon Bérard, Lyon, France|IUCT-oncopole, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02777710"
43,"NCT04195373","A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract",,"Not yet recruiting","No Results Available","Gastrointestinal Cancer","Biological: TMV-018 + 5-FC|Biological: TMV-018 + anti-PD-1|Biological: TMV-018 + 5-FC + anti-PD-1","Frequency of Adverse Events|Determine MTD and dose for phase II|Viral replication|Viral distribution|Efficacy of therapy assessed by RECIST 1.1|Efficacy of therapy assessed by changes in tumor marker level","Themis Bioscience GmbH|Assign Data Management and Biostatistics GmbH|SSS International Clinical Research GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMV-018-101","April 2020","December 2022","December 2024","December 11, 2019",,"December 11, 2019","University Hospital Bonn, Bonn, Germany|University Hospital Tübingen, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT04195373"
44,"NCT03325816","Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Small Cell Lung Cancer|Small Cell Lung Cancer Extensive Stage","Drug: Nivolumab|Radiation: 177Lu-DOTA0-Tyr3-Octreotate","Phase I - Recommended phase II dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate|Phase II - Progression Free Survival|Safety profile of 177Lu-DOTA0-Tyr3-Octreotate in combination with nivolumab|Phase II - Overall survival|Phase II - Disease Control Rate|Phase II - Objective Response Rate|Phase II - Metabolic Response","Georgetown University|Bristol-Myers Squibb|Advanced Accelerator Applications","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-1081","November 20, 2017","March 28, 2019","December 2020","October 30, 2017",,"February 19, 2020","Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03325816"
45,"NCT02734160","A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer",,"Completed","No Results Available","Metastatic Pancreatic Cancer","Drug: Galunisertib|Drug: Durvalumab","Number of Participants with Galunisertib in Combination with Durvalumab Dose-Limiting Toxicities (DLTs)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Galunisertib|PK: Area Under the Curve (AUC) at Steady State of Galunisertib|PK: Minimum Concentration (Cmin) of Durvalumab|Number of Participants with Anti-Durvalumab Antibodies|Progression-free Survival (PFS)|Objective Response Rate (ORR): Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR)|Duration of Response (DoR)|Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and Stable Disease (SD)|Time to Response|Overall Survival (OS)","Eli Lilly and Company|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15784|H9H-MC-JBEG|2015-005295-26","June 15, 2016","August 2, 2018","April 17, 2019","April 12, 2016",,"August 5, 2019","Honor Health Research Institute, Scottsdale, Arizona, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Gustave Roussy, Villejuif Cedex, France|Ospedale Policlinico Giambattista Rossi, Borgo Roma, Verona, Italy|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02734160"
46,"NCT03386526","APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies",,"Recruiting","No Results Available","Advanced Solid Tumors or Hematologic Malignancies","Drug: APG-1387 for Injection","Maximum Tolerated Dose (MTD)|Anti-tumor effects of APG-1387 as a single agent|Pharmacokinetic evaluation|Anti-tumor effects of APG-1387 in combination with pembrolizumab or combination with paclitaxel and carboplatin in patients with advanced solid tumors|Preliminary biomarker assessment","Ascentage Pharma Group Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","90","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APG-1387-US-001","November 21, 2017","September 11, 2020","December 11, 2020","December 29, 2017",,"May 29, 2020","START Midwest, Grand Rapids, Michigan, United States|The START Center for Cancer Care, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03386526"
47,"NCT03572478","Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer",,"Active, not recruiting","No Results Available","Prostate Cancer|Endometrial Cancer","Drug: Rucaparib|Drug: Nivolumab","Dose limiting toxicities (DLT) rate of the combination of rucaparib and nivolumab (phase 1)|Frequency of patients with T cell inflammation in the tumor compared between treatment arms (phase 2)|Time to disease progression in prostate cancer patients (phase 2)|Time to disease progression in endometrial cancer patients (phase 2)|Response rate in prostate cancer patients (phase 2)|Response rate in endometrial cancer patients (phase 2)|Changes in number of T cells in tumor samples compared between treatment arms (phase 2)|Correlation of change in T cells in tumor samples and PTEN mutation status (phase 2)","University of Chicago|Bristol-Myers Squibb|Clovis Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB18-0154","August 14, 2018","February 29, 2020","December 2021","June 28, 2018",,"May 22, 2020","University of Chicago Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03572478"
48,"NCT03996473","Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases",,"Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)|Drug: Pembrolizumab","Number of participants with adverse events (AEs) in Phase 1|Number of participants with dose limiting toxicities (DLTs) in Phase 1|Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Phase 2|ORR per RECIST v1.1 in Phase 1|ORR per iRECIST in Phase 1|Duration of response (DOR) per RECIST v1.1 in Phase 1|DOR per iRECIST in Phase 1|Disease control rate (DCR) per RECIST v1.1 in Phase 1|DCR per iRECIST in Phase 1|ORR per iRECIST in Phase 2|DOR per RECIST v1.1 in Phase 2|DOR per iRECIST in Phase 2|DCR per RECIST v1.1 in Phase 2|DCR per iRECIST in Phase 2|Progression free survival (PFS) per RECIST v1.1 in Phase 2|PFS per iRECIST in Phase 2|Overall survival (OS) in Phase 2|Number of participants with AE in Phase 2","Bayer|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19781|2018-003704-39","March 10, 2020","April 30, 2023","July 30, 2023","June 24, 2019",,"June 3, 2020","Highlands Oncology Group, PA, Fayetteville, Arkansas, United States|Ccare San Marcos Cancer Center & Urology, San Marcos, California, United States|Cancer Treatment Centers of America, Atlanta, Newnan, Georgia, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Regional Cancer Care Associates, LLC, Somerset, New Jersey, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Oncology/Hematology Care (OHC) Clinical Trials, LLC, Cincinnati, Ohio, United States|CTCA Southwestern, Tulsa, Oklahoma, United States|St. Luke's University Health Network System, Bethlehem, Pennsylvania, United States|UPMC Shadyside, Pittsburgh, Pennsylvania, United States|Carilion Clinic, Roanoke, Virginia, United States|UZ Brussel, Bruxelles - Brussel, Belgium|UZ Gent, Gent, Belgium|CHU de Liège, Liege, Belgium|CHU UCL Namur, Namur, Belgium|Universitätsklinikum der Johann Wolfgang Goethe Universität, Frankfurt, Hessen, Germany|Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany|Klinikum der Stadt Köln gGmbH - Krankenhaus Merheim, Köln, Nordrhein-Westfalen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Edith Wolfson Medical Center, Holon, Israel|Meir Medical Center, Kfar Saba, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|A.O.U. di Parma, Parma, Emilia-Romagna, Italy|IRCCS Istituto Europeo di Oncologia (IEO), Milano, Lombardia, Italy|IRCCS Fondazione Policlinico San Matteo, Pavia, Lombardia, Italy|Nederlands Kanker Instituut, Amsterdam, Netherlands|Centrum Onkologii im. Prof. Franciszka Lukaszczyka, Bydgoszcz, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Uniwersytecki Szpital Kliniczny UM we Wroclawiu, Wroclaw, Poland|Institut Català d'Oncologia Badalona, Badalona, Barcelona, Spain|Hospital Universitario Clinica Puerta de Hierro, Majadahonda, Madrid, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Leeds teaching Hospitals, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03996473"
49,"NCT04317105","Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN",,"Not yet recruiting","No Results Available","Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm","Drug: Copanlisib Hydrochloride|Biological: Ipilimumab|Biological: Nivolumab","Incidence of adverse events and serious adverse events|Incidence of dose limiting toxicities (DLTs)|Objective response (OR) rate (complete response [CR] + partial response [PR])|Clinical benefit rate (OR + stable disease [SD] > 6 months)|Progression free survival (PFS)|Overall survival (OS)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","102","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2020-01917|NCI10221|10221|UM1CA186688","May 6, 2020","December 31, 2022","December 31, 2022","March 23, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04317105"
50,"NCT02808650","Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",,"Active, not recruiting","No Results Available","Childhood Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Primary Central Nervous System Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Prexasertib","Maximum tolerated dose (MTD) of prexasertib based on incidence of dose limiting toxicity assessed National Cancer Institute (NCI) CTCAE version 4.0|Incidence of adverse events (toxicities) according to NCI CTCAE version 4.0|Pharmacodynamic parameters of prexasertib|Antitumor activity of prexasertib|CHK1/2 expression status|TP53 deletion and/or mutation in tumor tissue as a potential biomarker of Chk1 inhibition|Pharmacodynamic markers of prexasertib","Children's Oncology Group|National Cancer Institute (NCI)","All","12 Months to 21 Years   (Child, Adult)","Phase 1","30","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADVL1515|NCI-2016-00643|UM1CA097452","February 27, 2017","December 31, 2019","December 31, 2020","June 22, 2016",,"May 14, 2020","Children's Hospital of Alabama, Birmingham, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02808650"
51,"NCT03057145","Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors",,"Active, not recruiting","No Results Available","Solid Tumor","Drug: Prexasertib|Drug: Olaparib","Maximum Tolerated Dose|Dose Limiting Toxicity as assessed by CTCAEv4.0|Pharmacokinetic Sampling - Peak Plasma Concentration (Cmax)|Pharmacokinetic Sampling - Area Under the Plasma Concentration versus Time Curve (AUC)|Anti-Tumor Effects Of The Combination Of Prexasertib And Olaparib by RECIST 1.1|Phospho-CDK Expression In Tumor Biopsies As A Marker Of Prexasertib Effect And Downstream Marker Of Target Engagement|RAD51 Focus Formation and γ-H2AX Expression in tumor biopsies Post-Olaparib And Post-Combination Treatment as a marker of DNA damage","Khanh Do|Eli Lilly and Company|AstraZeneca|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","29","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-573","March 10, 2017","February 25, 2020","February 25, 2023","February 17, 2017",,"April 7, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03057145"
52,"NCT02812875","A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",,"Active, not recruiting","No Results Available","Advanced Solid Tumors or Lymphomas","Drug: CA-170","The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycle|Maximum tolerated dose (MTD) of CA-170|Recommended Phase 2 Dose (RP2D) of CA-170|Pharmacokinetic (PK) Profile of CA-170|Preliminary Anti-tumor Activity of CA-170 based on RECIST and Immune Related Response Criterion (irRC) for Solid Tumors or Cheson for Lymphoma","Curis, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","300","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA-170-101","May 2016","January 2020","January 2020","June 24, 2016",,"May 6, 2019","University of California San Francisco, San Francisco, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Sarah Cannon Research Institute, Sarasota, Florida, United States|Northwestern University, Chicago, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei University Health System - Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Clinic i Provincial, Barcelona, Spain|Catalan Institute of Oncology, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02812875"
53,"NCT04262466","Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors",,"Recruiting","No Results Available","Select Advanced Solid Tumors","Drug: IMC-F106C|Drug: anti-PD(L)1","Phase 1: Incidence of Dose-limiting toxicity (DLT)s|Phase 1: incidence and severity of adverse events (AE) and serious adverse events (SAE)|Phase 1: changes in laboratory parameters|Phase 1: changes in vital signs|Phase 1: changes in electrocardiogram parameters|Phase 1: dose interruptions, reductions, and discontinuations|Phase 2: Best overall response (BOR)|Phase I: Best Overall Response (BOR)|Progression-free survival (PFS)|Duration of response (DOR)|Overall survival|Pharmacokinetics Area under the plasma concentration-time curve (AUC)|Pharmacokinetics The maximum observed plasma drug concentration (Cmax)|Pharmacokinetics The time to reach maximum plasma concentration (Tmax)|Pharmacokinetics The elimination half-life (t1/2)|Incidence of anti-IMC-F106C antibody formation|Changes in lymphocyte counts over time|Changes in serum cytokines over time","Immunocore Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","170","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMC-F106C-101","February 25, 2020","February 2022","February 2024","February 10, 2020",,"April 21, 2020","University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04262466"
54,"NCT02797964","A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer",,"Completed","No Results Available","Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)","Drug: SRA737","Number of subjects with adverse events as assessed by CTCAE 4.03|Maximum tolerated dose of SRA737|Recommended Phase 2 dose of SRA737|Objective response rate of SRA737","Sierra Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","112","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRA737-01","July 2016","October 28, 2019",,"June 14, 2016",,"December 11, 2019","Royal Marsden Hospital, Sutton, London, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Oxford University Hospitals, Headington, Oxford, United Kingdom|Velindre Cancer Centre - Cardiff, Cardiff, Whitchurch, United Kingdom|The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|The Leeds Teaching Hospitals of St James University Hospital, Leeds, United Kingdom|University Hospitals of Leicester, Leicester, United Kingdom|Guy's and St. Thomas, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|University College London Hospitals, London, United Kingdom|The Christie, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02797964"
55,"NCT02439450","A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Biological: Viagenpumatucel-L|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Pemetrexed","Phase 1b: Frequency of treatment emergent adverse events (TEAEs) as assessed by CTCAE v4.03.|Phase 2, Arm 5: Objective Response Rate (ORR)|Phase 2, Arm 6: Progression Free Survival (PFS)|Objective Response Rate (ORR)|Overall survival (OS)|Progression-Free survival (PFS)|Duration of response (DOR)|Disease control rate (DCR)|Durable Response Rate (DRR)|Frequency of treatment emergent adverse events (TEAEs) as assessed by CTCAE v4.03.","Heat Biologics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","121","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS110-102","April 15, 2015","December 2020","December 2021","May 8, 2015",,"April 27, 2020","University of Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego, La Jolla, California, United States|BRRH Lynn Cancer Institute, Boca Raton, Florida, United States|Memorial Cancer Institute, Pembroke Pines, Florida, United States|Horizon Oncology Research, Lafayette, Indiana, United States|Ashland-Bellefonte Cancer Center, Ashland, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New York Oncology Hematology, Albany, New York, United States|Winthrop Hospital, Mineola, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02439450"
56,"NCT03583086","Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors",,"Recruiting","No Results Available","Thymic Carcinoma|Non-small Cell Lung Cancer|Refractory Thoracic Tumors|Small-Cell Lung Cancer","Drug: VEGFR/PDGFR Dual Kinase Inhibitor X-82|Biological: Nivolumab","Phase II recommended combination dose per Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.03|Phase II best response per Response Evaluation Criteria in Solid Tumors (RECIST)|Phase II best response|Progression-free survival|Overall survival|Objective response rate as related to PD-L1 status measured as < 1%, 1-49%, and > 50%.|Disease control rate","Vanderbilt-Ingram Cancer Center|Bristol-Myers Squibb|Xcovery Holdings, INC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","177","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC THO 1802|CA209-982","July 10, 2018","July 2023","July 2024","July 11, 2018",,"May 18, 2020","Stanford Cancer Institute, Palo Alto, California, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Baptist Clinical Research Institute, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03583086"
57,"NCT02404441","Phase I/II Study of PDR001 in Patients With Advanced Malignancies",,"Active, not recruiting","No Results Available","Melanoma|NSCLC|Triple Negative Breast Cancer|Anaplastic Thyroid Cancer|Other Solid Tumors","Biological: PDR001","Part l: The exposure (AUC(0-336h)) after first dose of treatment|Part l: Incidence of dose limiting toxicities (DLTs)|Part ll: Overall response Rate (ORR)|Presence and/or concentration of anti-PDR001|Overall Response Rate (ORR) - Phase l only|Progression Free Survival (PFS) - Phase l/ll|Duration of Response (DOR) - Phase l/ll|Disease Control Rate (DCR) - Phase l/ll|Overall Response Rate (ORR) per immune related Response Criteria - Phase ll only|Serum pharmacokinetic (PK) parameter AUCs|Serum Pharmacokinetic (PK) parameter Cmax|Serum Pharmacokinetic (PK) parameter Tmax","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","319","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPDR001X2101|2014-003929-17","April 27, 2015","July 1, 2020","July 3, 2020","March 31, 2015",,"April 21, 2020","The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Houston, Texas, United States|Huntsman Cancer Institute Univ. of Utah HCI, Salt Lake City, Utah, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Edirne, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT02404441"
58,"NCT04246671","Phase 1/2 Trial of Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients",,"Not yet recruiting","No Results Available","Breast Cancer|Gastric Cancer|Cancer","Biological: TAEK-VAC-HerBy","Patients with Dose Limiting Toxicity (DLT)","Bavarian Nordic","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAEK-VAC-HerBy-001 Phase 1","June 30, 2020","December 2022","December 2024","January 29, 2020",,"January 29, 2020",,,"https://ClinicalTrials.gov/show/NCT04246671"
59,"NCT02502708","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors",,"Completed","No Results Available","Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma|Primary CNS Tumor","Drug: Indoximod|Drug: Temozolomide|Radiation: Conformal Radiation|Drug: Cyclophosphamide|Drug: Etoposide","Incidence of regimen limiting toxicities (RLTs)|Objective Response Rate|Safety and tolerability assessed by development of AEs and laboratory parameters of indoximod in combination with cyclophosphamide and etoposide.|Pharmacokinetics: Serum concentrations (Cmax/Steady State)|Safety and Tolerability of Indoximod combined with Temozolomide as assessed by incidence and severity of adverse events, dose interruptions and dose reductions.|Progression Free Survival (PFS)|Time to Progression|Overall Survival|Safety and Feasibility of Indoximod combined with conformal radiation as assessed by incidence and severity of adverse events, dose interruptions and dose reductions.","NewLink Genetics Corporation|Lumos Pharma","All","3 Years to 21 Years   (Child, Adult)","Phase 1","81","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG2105","October 2015","December 12, 2019","February 28, 2020","July 20, 2015",,"June 4, 2020","Children's Hospital Colorado, Aurora, Colorado, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Children's Heathcare of Atlanta, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02502708"
60,"NCT03168139","Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer","Keynote-559","Completed","No Results Available","Metastatic Colorectal Cancer|Metastatic Pancreatic Cancer","Drug: Olaptesed pegol - Monotherapy|Drug: Olaptesed pegol + Pembrolizumab - Combination Therapy","Monotherapy: Pharmacodynamics|Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratory|Monotherapy: Safety|Combination Therapy: Disease control rate (DCR)|Combination Therapy: Efficacy - time to event analyses","NOXXON Pharma AG|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNOXA12C601|2016-003657-15","April 18, 2017","March 25, 2020","March 25, 2020","May 30, 2017",,"April 30, 2020","Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT03168139"
61,"NCT03539822","Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)",,"Recruiting","No Results Available","Gastric Cancer|Esophageal Adenocarcinoma|Hepatocellular Carcinoma|Colorectal Cancer","Drug: Cabozantinib|Drug: Durvalumab","Maximum Tolerated Dose (MTD)|Proportion of participants with adverse events (AEs).|Overall Response Rate (ORR)|Overall Benefit Rate (OBR)|Progression Free Survival (PFS)|Overall Survival (OS)","Anwaar Saeed|AstraZeneca|Exelixis|University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT-2017-Cabozant+DurvaGI","September 14, 2018","June 30, 2020","December 30, 2020","May 29, 2018",,"September 30, 2019","The University of Kansas Cancer Center, Fairway, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03539822"
62,"NCT03277638","Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)",,"Recruiting","No Results Available","Glioblastoma, Adult","Drug: Pembrolizumab at 7 days prior|Drug: Pembrolizumab at 14 days post|Drug: Pembrolizumab at 35 days post|Procedure: Laser Interstitial Thermotherapy","Phase I Objective: Optimal timing of LITT with pembrolizumab|Phase II Objective: Tumor Response|Progression free survival|overall survival|The proportion of patients who achieve progression free survival at 6 months (PFS6)|The proportion of patients who achieve progression free survival at 12 months (PFS12)|The proportion of patients who achieve progression free survival at 24 months (PFS24)","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE3316","November 29, 2017","May 2020","July 2020","September 11, 2017",,"January 3, 2020","University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03277638"
63,"NCT03233724","Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",,"Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-Small Cell Lung Cancer|Carcinoma, Esophageal","Drug: Decitabine (DAC)|Drug: Tetrahydrouridine (THU)|Drug: Pembrolizumab","Maximum tolerated dose|Overall response rate|Examine if oral DAC-THU modulates DNA methylation, as well as gene, micro-RNA, and endogenous retroviral expression profiles of lungcancer and EsC cells and alters the tumor micro-environment|Examine if oral DAC-THU modulates plasma tumor DNA methylation, circulating tumor cells and peripheral immune subsets","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","75","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170140|17-C-0140","April 11, 2018","December 31, 2025","December 31, 2025","July 31, 2017",,"May 13, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03233724"
64,"NCT04393506","Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma",,"Recruiting","No Results Available","Oral Cancer|VEGFR2 Inhibitor|Programmed Cell Death 1 Inhibitor|Inductive Therapy","Drug: Camrelizumab|Drug: Apatinib|Procedure: Radical surgery|Radiation: Post-operative radiotherapy/chemoradiotherapy","Major pathologic response|2-year overall survival|2-year tumor recurrence rate","Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Icemelting trial","April 23, 2020","December 31, 2020","December 31, 2023","May 19, 2020",,"May 19, 2020","Shanghai Ninth People's Hospital, Shanghai, Shanghai, China","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT04393506/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04393506"
65,"NCT03366844","Breast Cancer Study of Preoperative Pembrolizumab + Radiation",,"Recruiting","No Results Available","Breast Cancer","Drug: Pembrolizumab|Radiation: RT Boost","Number of patients who do not necessitate a delay in standard of care treatment after receiving the investigational combination of preoperative Pembrolizumab and radiation|Changes in Tumor Infiltrating Lymphocytes (TIL)|Pembrolizumab-related adverse events|Immune-related adverse events|Invasive disease-free survival after preoperative radiation and Pembrolizumab|Pathological complete response rate","Stephen Shiao|United States Department of Defense|Cedars-Sinai Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT2017-07-HO-PembroRT","December 22, 2017","January 1, 2021","January 1, 2021","December 8, 2017",,"March 6, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03366844/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03366844"
66,"NCT04407741","Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas",,"Not yet recruiting","No Results Available","Solid Tumor|Lymphoma","Drug: SHR2554+SHR1701|Drug: SHR1701","Median amount of time subject survives without disease progression following the initiation of treatment|Number of subjects with treatment related adverse events as assessed by CTCAE v5.0.|The percentage of subjects respond to treatment.|Median amount of times subjects alive after treatment","Chinese PLA General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHN-PLAGH-BT-055","June 1, 2020","June 1, 2022","June 1, 2023","May 29, 2020",,"May 29, 2020","Department of Biotherapeutic, Chinese PLA General Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04407741"
67,"NCT02671435","A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors",,"Active, not recruiting","No Results Available","Advanced Solid Tumors","Combination Product: Intervention","Occurrence of Drug Limited Toxicities (DLTs)|Number of patients with changes in vital signs from baseline|Occurrence of adverse events (AEs)|Number of patients with changes in electrocariogram (ECG) from baseline|Occurrence of serious adverse events (SAEs)|Number of patients with changes in laboratory parameters from baseline|Objective Response Rate (ORR)|Expression of pre-treatment protein within the tumor microenvironment|Number of subjects who develop anti-drug antibodies|Durva, monalizumab, biologic agent serum peak concentration (cMax) concentration for Pharmacokinetics|Durva and monalizumab serum area under the concentration-time curve (AUC) concentration for Pharmacokinetics|Durva and monalizumab serum clearance (CL) concentration for Pharmacokinetics|Durva and monalizumab serum terminal elimination half-life (t1/2) concentration for Pharmacokinetics|Progression Free Survival (PFS)|Disease Control Rate (DC)|Overall Survival (OS)|Duration of Response (DoR)","MedImmune LLC","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","383","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D419NC00001","February 22, 2016","March 14, 2022","March 14, 2022","February 2, 2016",,"April 20, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Duarte, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Monica, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Lake Success, New York, United States|Research Site, New York, New York, United States|Research Site, Providence, Rhode Island, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Blacktown, Australia|Research Site, Clayton, Australia|Research Site, Waratah, Australia|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Marseille CEDEX 5, France|Research Site, Nantes CEDEX 1, France|Research Site, Debrecen, Hungary|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Grafton, New Zealand|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Pamplona, Spain|Research Site, Sevilla, Spain|Research Site, London, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02671435"
68,"NCT03144778","Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer",,"Active, not recruiting","No Results Available","Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7","Biological: Durvalumab|Biological: Tremelimumab","Change of CD8+ tumor infiltrating lymphocytes|Incidence of adverse events and serious adverse events|Overall response rate|Mean MD Anderson Symptom Inventory Head and Neck Cancer (MDASI-HN)|Percentage of viable tumor cells in the surgical specimen","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0805|NCI-2018-01199|P30CA016672","July 12, 2017","August 31, 2020","August 31, 2020","May 9, 2017",,"January 29, 2020","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03144778"
69,"NCT03474640","Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies",,"Recruiting","No Results Available","Advanced Malignancies","Biological: Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Progression-Free survival (PFS)|Overall survival (OS)","Shanghai Junshi Bioscience Co., Ltd.|TopAlliance Biosciences, Inc.|Iqvia Pty Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1","258","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAB001-01","March 14, 2018","August 2020","August 2020","March 22, 2018",,"February 17, 2020","UCSD Moores Cancer Center, La Jolla, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Miami Hospital Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic-Rochester, Rochester, Minnesota, United States|Columbia Weill Cornell Cancer Centers, New York, New York, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03474640"
70,"NCT03296137","Adoptive Cell Therapy Across Cancer Diagnoses",,"Active, not recruiting","No Results Available","Cancer","Biological: Autologous tumor-infiltrating lymphocytes|Drug: Ipilimumab|Drug: Nivolumab|Drug: proleukin|Drug: Cyclophosphamide|Drug: Fludara","Number and type of reported adverse events|Treatment response, progressive disease|Treatment response, surival|Treatment related immune response","Inge Marie Svane|Herlev Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AA1720","October 13, 2017","November 6, 2019","June 6, 2020","September 28, 2017",,"January 7, 2020","Center for Cancer immune Therapy (CCIT), Dept. of Hematology and dept. of Oncology, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03296137"
71,"NCT02571725","PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer",,"Recruiting","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms","Drug: Olaparib|Drug: Tremelimumab","Phase 1: Recommended Phase 2 Dose (RP2D)|Phase 2: Objective response rate (ORR)|Phase 2: Progression free survival (PFS)","New Mexico Cancer Care Alliance","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INST 1419","February 2016","February 2020","February 2022","October 8, 2015",,"June 17, 2019","Moffitt Cancer Center, Tampa, Florida, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|The Ohio State University, Columbus, Ohio, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02571725"
72,"NCT04060407","CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)","CINDI","Not yet recruiting","No Results Available","Metastatic Melanoma|Renal Cell Carcinoma|Colon Cancer With MSI-H or dMMR","Drug: CD24Fc|Drug: Ipilimumab|Drug: Nivolumab","Safety and tolerability of combination of CD24Fc with Ipilimumab and Nivolumab|Profile of treatment related adverse events|The Objective Response Rate (OPR)|The Progression Free Survival (PFS)|The Overall Survival (OS)","OncoImmune, Inc.|Huntsman Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD24-004-CINDI","September 1, 2020","December 30, 2022","December 30, 2023","August 19, 2019",,"June 3, 2020","Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04060407"
73,"NCT02793466","Durvalumab in Pediatric and Adolescent Patients",,"Recruiting","No Results Available","Solid Tumor|Lymphoma|Central Nervous System Tumors","Drug: Durvalumab; MEDI4736","Maximum Tolerated Dose (MTD)|Dose Limiting Toxicity (DLT)|Safety Profile|Maximum Plasma Concentration (CMax)|Area under the curve (AUC)|Minimum Plasma Concentration (CTrough)|Response rate|Drug antibody level|Suppression of free soluble PD-L1 suppression in serum|Duration of response","Children's Hospital Los Angeles","All","1 Year to 17 Years   (Child)","Phase 1","36","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ESR-14-10488","July 2016","December 2019","December 2020","June 8, 2016",,"January 30, 2019","Children's Hospital Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02793466"
74,"NCT04250155","An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",,"Recruiting","No Results Available","Solid Tumors","Drug: XmAb24306|Drug: Atezolizumab","Percentage of Participants with Adverse Events|Serum Concentration of XmAb24306|Objective Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1|Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1|Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1|ORR as Based on Radiographic Assessment by the Investigator Using Modified RECIST v1.1 for Immune-Based Therapeutics (iRECIST)|DOR as Based on Radiographic Assessment by the Investigator Using iRECIST|PFS as Based on Radiographic Assessment by the Investigator Using iRECIST|Overall Survival (OS)","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","250","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO41596","March 9, 2020","June 1, 2024","June 1, 2024","January 31, 2020",,"May 22, 2020","Honor Health Research Institute, Scottsdale, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Peter Mac Callum Cancer Center, East Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT04250155"
75,"NCT04000529","Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",,"Recruiting","No Results Available","Non-small Cell Lung Carcinoma|Head and Neck Squamous Cell Carcinoma|Esophageal SCC|Gastrointestinal Stromal Tumors|Colorectal Cancer","Drug: TNO155|Drug: Spartalizumab|Drug: Ribociclib","DLT incidence|AE and SAE incidence|Dose interruptions, reductions and dose intensity, by treatment|Pharmacokinetics (PK): Cmax|Pharmacokinetics (PK): Tmax|Pharmacokinetics (PK): AUClast|Pharmacokinetics (PK): AUCtau|Efficacy measurements per RECIST v1.1: ORR|Efficacy measurements per RECIST v1.1: DCR|Efficacy measurements per RECIST v1.1: PFS|Efficacy measurements per RECIST v1.1: DOR|Efficacy measurements per iRECIST: ORR|Efficacy measurements per iRECIST: DCR|Efficacy measurements per iRECIST: PFS|Efficacy measurements per iRECIST: DOR|Overall Survival","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","126","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTNO155B12101","July 30, 2019","March 22, 2022","March 22, 2022","June 27, 2019",,"April 21, 2020","Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Chuo ku, Tokyo, Japan|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain",,"https://ClinicalTrials.gov/show/NCT04000529"
76,"NCT02546531","Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer",,"Active, not recruiting","No Results Available","Advanced Solid Tumors|Solid Tumors|Pancreatic Cancer","Biological: Defactinib|Biological: Pembrolizumab|Drug: Gemcitabine","Recommended phase II dose|Safety and toxicity as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Objective response rate (ORR) in dose escalation cohort|Objective response rate (ORR) in dose expansion cohort|Treatment duration in dose escalation cohort|Treatment duration in dose expansion cohort|Progression-free survival (PFS) in dose escalation cohort|Progression-free survival in dose expansion cohort|Overall survival (OS) in dose escalation cohort|Overall survival in dose expansion cohort|Immune-related PFS in dose escalation cohort|Immune-related PFS in dose expansion cohort","Washington University School of Medicine|Barnes Jewish Health Foundation|Merck Sharp & Dohme Corp.|Verastem, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201510157","February 3, 2016","November 17, 2017","July 31, 2020","September 11, 2015",,"November 6, 2019","Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02546531"
77,"NCT03362060","PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer",,"Recruiting","No Results Available","Triple Negative Breast Cancer|Metastatic Breast Cancer","Drug: Pembrolizumab|Biological: PVX-410","Immune Response following treatment with PVX-410 in combination with pembrolizumab|Late Immune response after treatment with PVX-410 and pembrolizumab|Incidence of treatment emergent adverse events (safety and tolerability) of PVX-410 in combination with pembrolizumab|Progression Free Survival|Overall Survival|Response rate|Disease Control Rate|Clinical Benefit Rate|Duration of response","Massachusetts General Hospital|Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-328","December 12, 2017","December 31, 2021","December 31, 2024","December 5, 2017",,"August 26, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03362060"
78,"NCT02838823","Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer",,"Completed","No Results Available","Breast Cancer","Biological: humanized anti-PD-1 monoclonal antibody toripalimab","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|PD-1 receptor occupancy of blood|Objective Response Rate (ORR) by irRC and RECIST 1.1|Duration of Response (DOR) by irRC and RECIST 1.1|Disease Control Rate (DCR) by irRC and RECIST 1.1|Time to response (TTR) by irRC and RECIST 1.1|Progression-free survival(PFS) by irRC and RECIST 1.1|Overall survival (OS) by irRC and RECIST 1.1|Maximum Plasma Concentration (Cmax) after single dose injection of Anti-PD-1 Monoclonal Antibody (mAb)|Peak Time (Tmax) after single dose injection of Anti-PD-1 mAb|Area Under the Curve (AUC) after single dose injection of Anti-PD-1 mAb Area Under the Curve [AUC]). Area Under the Curve (AUC) after single dose injection of Recombinant Humanized Anti-PD-1 Monoclonal An|t1/2 after single dose injection of Recombinant Humanized Anti-PD-1 mAb|Plasma clearance (CL) after single dose injection of Anti-PD-1 mAb|Apparent volume of distribution (V) after single dose injection of Anti-PD-1 mAb|Minimum Plasma Concentration (Cmin) of steady state after multiple dose injection of Anti-PD-1 mAb|Average Plasma Concentration (Cav) of steady state after multiple dose injection of Anti-PD-1 mAb|degree of fluctuation (DF) of steady state after multiple dose injection of Anti-PD-1 mAb|Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb","Shanghai Junshi Bioscience Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Junshi-JS001-307-I","July 2016","December 2018","September 2019","July 20, 2016",,"October 23, 2019","Gastrointestinal Oncology Department, Affiliated Cancer Center of Academy of Military Medical Sciences, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02838823"
79,"NCT03743298","Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma",,"Not yet recruiting","No Results Available","Metastatic Melanoma","Drug: AV-MEL-1","Primary Safety Endpoint: Number of grade 3-5 adverse events with AV-MEL-1 + PD-1 versus PD-1 alone","Aivita Biomedical, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CL-MEL-P01-US","June 2019","June 2020","January 2023","November 16, 2018",,"January 7, 2019",,,"https://ClinicalTrials.gov/show/NCT03743298"
80,"NCT03298893","Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months","NiCOL","Recruiting","No Results Available","Cervical Cancer|Locally Advanced Cervical Cancer","Drug: Nivolumab Injection|Drug: Cisplatin|Radiation: radiotherapy","rate of occurrence of dose-limiting toxicity (DLT)|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Disease Free Survival (DFS)|Incidence of Serious Adverse Events (SAEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy|Incidence of Adverse Events (AEs) to assess the overall safety profile of the association of nivolumab and pelvic radio-chemotherapy|validation of molecular alterations detected by molecular analyses|ctDNA heterogeneity|tumor microenvironment description|tumor PD-L1 immunohistochemistry","Institut Curie|Bristol-Myers Squibb","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","21","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IC 2016-08","November 27, 2017","May 2020","May 2022","October 2, 2017",,"November 25, 2019","Institut Curie, Paris, France|Hopital Européen Georges Pompidou, Paris, France|Institut Curie Hopital René Huguenin, Saint Cloud, France",,"https://ClinicalTrials.gov/show/NCT03298893"
81,"NCT04332653","NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","KEYNOTE A60","Not yet recruiting","No Results Available","Any Advanced Solid Tumors|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Small Cell Lung Cancer|Microsatellite Stable Colorectal Cancer|Pancreatic Cancer","Drug: NT-I7|Drug: Pembrolizumab","Phase 1b: Safety and Tolerability of NT-I7 in Combination With Pembrolizumab to Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7|Phase 2a: Preliminary Assessment of the Objective Response Rate (ORR) of NT-I7 in Combination with Pembrolizumab|Duration of Objective Response (DOR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants Who Experience an Increase in Anti-Drug Antibodies (ADAs) to NT-I7","NeoImmuneTech","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","168","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIT-110 (PNA60)","July 15, 2020","June 30, 2022","April 30, 2023","April 3, 2020",,"May 15, 2020","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04332653"
82,"NCT02484404","Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers",,"Recruiting","No Results Available","Colorectal Neoplasms|Breast Neoplasms","Drug: Olaparib|Drug: Cediranib|Drug: MEDI4736","Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of MEDI4736/olaparib (MEDI-O) and MEDI4736/cediranib (MEDI-C) in patients with advanced solid tumors|Ph II Determine overall response rate of MED-O and MEDI-C in patients with recurrent ovarian cancer|Ph I doublet tx: determin the safety of the doublets, MEDI+O and MEDI+C|Ph I doublet tx:determine preliminary response rates of the doublets using RECIST v1.1|Ph I doublet tx: determine the pharmacokinetics of the doublets and correlate with safety.|Ph I doublet tx: explore changes in peripheral immune subsets, plasma cytokines and circulating endothelial cells with safety and/or clinical outcome of MEDI+C|Ph I doublet:determine the potential relationship between PD-L1 expression obtained from archival tissue samples and clinical response|Ph I of triplet tx: determine the safety of MEDI+O+C|Ph I of triplet tx: determine preliminary response rates of MEDI+O+C using RECIST v1.1|Ph I of triplet tx:determine the pharmacokinetics of the triplet and correlate with safety.|Ph I of triplet tx: explore changes in peripheral immune subsets, plasma cytokines and circulating endothelial cells with safety and/or clinical outcome of MEDI+O+C|Ph I of triplet tx: determine the potential relationship between PD-L1 expression obtained from archival tissue samples and clinical response|Ph II Cohort 1 OvCa; MEDI+O, MEDI+C and MEDI+O+C arms: To evaluate PFS, safety by CTCAE v4.0, and potential relationship between pretreatment tumor PD-L1 expression obtained from biopsies and clinical response|Ph II Cohort 2 NSCLC; MEDI+O and MEDI+C arms: To determine ORR, and safety by CTCAE v4.0|Ph II Cohort 3 SCLC; MEDI+O arm: To determine PFS and safety by CTCAE v4.0|Ph II Cohort 4 mCRPC; MEDI+O arm: To determine ORR, safety by CTCAE v4.0, duration of response and PSA responses.|Ph II Cohort 5 TNBC; MEDI+O arm: To determine PFS, safety by CTCAE v4.0, and potential relationship between pretreatment tumor PD-L1 expression obtained from biopsies and clinical response","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","384","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150145|15-C-0145","June 29, 2015","July 29, 2021","June 29, 2022","June 29, 2015",,"May 15, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02484404"
83,"NCT01139775","A Study in Non Small Cell Lung Cancer",,"Completed","Has Results","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: LY2603618","Phase 2: Progression-Free Survival Time|Phase 1: Recommended Phase 2 Dose of LY2603618|Phase 2: Overall Survival|Phase 2: Overall Tumor Response Rate: Percentage of Participants Who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR)|Phase 2: Change in Tumor Size|Phase 1: Pharmacokinetic: Maximum Plasma Concentration (Cmax) (LY2603618)|Phase 1: Pharmacokinetic: Cmax (Pemetrexed and Cisplatin)|Phase 1: Pharmacokinetic: Area Under the Plasma Concentration Versus Time Curve (AUC) (LY2603618)|Phase 1: Pharmacokinetic: AUC (Pemetrexed and Cisplatin)|Phase 2: Pharmacokinetic: Cmax (LY2603618)|Phase 2: Pharmacokinetic: AUC (LY2603618)|Phase 2: Change From Baseline to Long-term Follow up in Lung Cancer Symptom Scale (LCSS)|Phase 1: Document Any Antitumor Activity Per Radiological Scans and/or Tumor Markers|Phase 2: Proportion of Participants Receiving Maintenance Therapy|Phase 2: Clinical Benefit Rate: Percentage of Participant Who Achieved a Response of Stable Disease (SD), Partial Response (PR), or Complete Response (CR)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13797|I2I-MC-JMMG","February 2011","May 2013","August 2014","June 9, 2010","May 18, 2018","May 18, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Baden-Wurttemberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munster, Nordhein-Westfalen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coswig, Sachsen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Homburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Immenhausen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lübeck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rheine, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Asturias, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mataro, Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pozuelo de Alarcon, Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Girona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01139775"
84,"NCT04187872","LITT and Pembrolizumab in Recurrent Brain Metastasis","TORCH","Recruiting","No Results Available","Melanoma|Non-small Cell Lung Carcinoma (NSCLC)|Renal Cell Carcinoma (RCC)|Small-cell Lung Cancer|Head and Neck Squamous Cell Cancer|Classical Hodgkin Lymphoma|Primary Mediastinal Large B-Cell Lymphoma|Urothelial Carcinoma|Microsatellite Instability-High Cancer|Gastric Cancer|Esophageal Cancer|Cervical Cancer|Hepatocellular Carcinoma|Merkel Cell Carcinoma|Brain Metastases, Adult","Combination Product: LITT + Pembrolizumab","Immune Effect of LITT plus pembrolizumab|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) of LITT plus pembrolizumab","University of Florida|Monteris Medical","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201902411|OCR26353","January 10, 2020","January 2022","October 2023","December 5, 2019",,"May 6, 2020","McKnight Brain Institute of the University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04187872"
85,"NCT03523572","Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer",,"Recruiting","No Results Available","Breast Cancer|Urothelial Carcinoma","Drug: Trastuzumab deruxtecan|Drug: Nivolumab","Part 1: Number of participants with dose-limiting toxicity at each dose level|Part 2: Dose expansion - Objective response rate (ORR) as assessed by Central Imaging Review|Number of participants with treatment emergent adverse events (TEAEs) during the trial|Duration of Response (DoR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Time to Response based on central review|Overall Survival (OS)|ORR","Daiichi Sankyo, Inc.|Bristol-Myers Squibb|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1","99","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DS8201-A-U105|2018-000371-32","June 20, 2018","September 2020","September 2020","May 14, 2018",,"May 21, 2020","UCLA - Medical Center, Santa Monica, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami Hospital & Clinics/Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Levine Cancer Institute Carolinas Healthcare System, Charlotte, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Tennessee Oncology - Sara Cannon Research Institute, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington Medical Center, Seattle, Washington, United States|AZ Groeninge, Kortrijk, West-Vlaanderen, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|GZA Hospital Campus Sint-Augustinus, Wilrijk, Belgium|Centre Georges Francois Leclerc, Dijon, France|ICO Rene Gauducheau, Saint-Herblain, France|Charite Campus Benjamin Franklin, Berlin, Brandenburg, Germany|University Hospital Frankfurt, Frankfurt, Hessen, Germany|University Cancer Center, Dresden, Sachsen, Germany|Ospedale San Raffaele, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Azienda Ospedaliera Universitaria Senese U.O.C. Immunoterapia Oncologica, Siena, Italy|Hospital Gregorio Maranon Madrid Spain, Madrid, Spain|MD Anderson Cancer Center Madrid, Madrid, Spain|Hospital Universitario Ramon y Cajal Madrid, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|START Madrid CIOCC, Madrid, Spain|Sarah Cannon Research Institute UK, London, England, United Kingdom|Royal Marsden Hospital (Surrey), London Borough of Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03523572"
86,"NCT03288545","A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","EV-103","Recruiting","No Results Available","Carcinoma, Transitional Cell|Urinary Bladder Neoplasms|Urologic Neoplasms|Renal Pelvis Neoplasms|Urothelial Cancer|Ureteral Neoplasms|Urethral Neoplasms","Drug: enfortumab vedotin (EV)|Drug: pembrolizumab|Drug: cisplatin|Drug: carboplatin|Drug: gemcitabine","Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|Pathological complete response (pCR) rate per local pathology review (MIBC coohorts only)|Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR)|Incidence of dose-limiting toxicity (DLT)|Confirmed ORR by investigator assessment according to RECIST 1.1 (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|ORR by BICR according to RECIST 1.1 (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|Confirmed ORR per the modified RECIST 1.1 for immune-based therapeutics (iRECIST) (Dose escalation and Part 1-3 cohorts with pembrolizumab only)|Disease control rate (DCR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)|DCR by BICR according to RECIST 1.1 (la/mUC cohorts only)|DCR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts using pembrolizumab only)|Duration of response (DOR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)|DOR by BICR according to RECIST 1.1 (la/mUC cohorts only)|DOR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only)|Progression free survival on study therapy (PFS1) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)|Progression free survival on study therapy (PFS1) by BICR according to RECIST 1.1 (la/mUC cohorts only)|PFS1 by investigator assessment according to iRECIST (Dose expansion and Part 1-3 cohorts with pembrolizumab only)|Progression free survival (PFS) on study therapy by investigator assessment according to RECIST 1.1 (MIBC cohorts only)|Overall survival (OS) (all cohorts)|Pharmacokinetics (PK) parameter for enfortumab vedotin: Maximum concentration (Cmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized (la/mUC cohorts only)|PK parameter for monomethyl auristatin E (MMAE): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|PK parameter for enfortumab vedotin: Time to maximum concentration (Tmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|PK parameter for MMAE: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|PK parameter for enfortumab vedotin: Area under the concentration-time curve (AUC) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|PK parameter for MMAE: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|Incidence of antitherapeutic antibodies (ATA) to enfortumab vedotin (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)|pCR rate by central pathology review (MIBC cohorts only)|PaR rate by local pathology review (MIBC cohorts only)|Pathological response (PaR) rate by central pathology review (MIBC cohorts only)|Disease-free survival (DFS) by investigator assessment according to RECIST 1.1 (MIBC cohorts only)|Type, incidence, severity, seriousness, and relatedness of AEs (Randomized Cohort K and MIBC cohorts only)|Type, incidence, and severity of laboratory abnormalities (Randomized Cohort K and MIBC cohorts only)|Percentage of planned surgeries delayed due to treatment-related AEs (MIBC cohorts only)","Astellas Pharma Global Development, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","407","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN22E-002","October 11, 2017","July 2023","March 2026","September 20, 2017",,"May 14, 2020","Alaska Urological Institute, Anchorage, Alaska, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|UC San Diego / Moores Cancer Center, La Jolla, California, United States|University of California Irvine - Newport, Orange, California, United States|University of California at San Francisco, San Francisco, California, United States|Stanford Cancer Center / Blood & Marrow Transplant Program, Stanford, California, United States|University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States|Decatur Memorial Hospital - Illinois, Decatur, Illinois, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University (NYU) Cancer Institute, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Case Western Reserve University / University Hospitals Case Medical Center, Cleveland, Ohio, United States|Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina, United States|Medical College of Wisconsin (Milwaukee), Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03288545"
87,"NCT02900664","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)",,"Active, not recruiting","No Results Available","Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma","Biological: PDR001|Biological: ACZ885|Biological: CJM112|Drug: TMT212|Drug: EGF816","Frequency of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety|Changes between baseline and post-baseline laboratory parameters and vital signs.|Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)|Frequency of dose interruptions|Dose intensities|Severity of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety|Frequency of dose reductions|Key secondary: Histopathology of tumor infiltrating lymphocytes (TILs)|Changes from baseline in electrocardiogram (ECG) parameters|Best overall response (BOR)|Progression free survival (PFS) per irRC and RECIST v1.1|Treatment Free Survival (TFS)|Presence and/or concentration of anti-PDR001 antibodies.|Serum concentration of PDR001, canakinumab, CJM112|Plasma concentrations of trametinib and EGF816|Key secondary: Histopathology of myeloid cell infiltrate by IHC (such as CD8, FoxP3 and myeloid markers as appropriate).|PK parameters (Eg. TMax) of EGF816|PK parameters (Eg. TMax) of trametinib|PK parameter (Eg. TMax) of PDR001|PK parameters (Eg. TMax) of canakinumab|PK parameters (Eg. TMax) of CJM112|Presence and/or concentration of anti-canakinumab antibodies.|Presence and/or concentration of anti-CJM112 antibodies.","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","290","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPDR001X2103|2016-000633-49","August 23, 2016","June 12, 2020","June 14, 2020","September 14, 2016",,"February 27, 2020","Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT02900664"
88,"NCT02836795","Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors",,"Active, not recruiting","No Results Available","Melanoma|Urological Cancer","Biological: humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|PD-1 receptor occupancy of blood|Objective Response Rate (ORR) by irRC and RECIST 1.1|Duration of Response (DOR) by irRC and RECIST 1.1|Disease Control Rate (DCR) by irRC and RECIST 1.1|Time to response (TTR) by irRC and RECIST 1.1|Progression-free survival(PFS) by irRC and RECIST 1.1|Overall survival (OS) by irRC and RECIST 1.1|Maximum Plasma Concentration (Cmax) after single dose injection of Anti-PD-1 Monoclonal Antibody (mAb)|Peak Time (Tmax) after single dose injection of Anti-PD-1 mAb|Area Under the Curve (AUC) after single dose injection of Anti-PD-1 mAb|t1/2 after single dose injection of Recombinant Humanized Anti-PD-1 mAb|Plasma clearance (CL) after single dose injection of Anti-PD-1 mAb|Apparent volume of distribution (V) after single dose injection of Anti-PD-1 mAb|Minimum Plasma Concentration (Cmin) of steady state after multiple dose injection of Anti-PD-1 mAb|Average Plasma Concentration (Cav) of steady state after multiple dose injection of Anti-PD-1 mAb|degree of fluctuation (DF) of steady state after multiple dose injection of Anti-PD-1 mAb|Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb","Shanghai Junshi Bioscience Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Junshi-JS001-BJZL-I","April 2016","September 2018","September 2020","July 19, 2016",,"October 22, 2019","Beijing Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02836795"
89,"NCT01416038","Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer",,"Completed","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer","Biological: DPX-Survivac|Drug: low dose cyclophosphamide (oral)","Number of reported adverse events|Levels of cell mediated immunity targeting the survivin epitopes","ImmunoVaccine Technologies, Inc. (IMV Inc.)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONC-DPX-Survivac-01","December 2011","May 2013","May 2013","August 12, 2011",,"April 21, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01416038"
90,"NCT03468426","A Study to Test Different Doses of BI 836880 Combined With BI 754091 in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours",,"Recruiting","No Results Available","Non-squamous, Non-Small-Cell Lung Cancer|Neoplasms","Drug: BI 836880|Drug: BI 754091","PART 1: Number of patients with Dose Limiting Toxicities (DLTs) within the first cycle of treatment|PART 2: Shrinkage estimator of objective response|PART 1:Adverse events (AEs), drug related AEs, drug related AEs leading to dose reduction or discontinuation during treatment period|PART 1: AUC 0-504h (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours after the first and fourth infusion cycle)|PART 2:Adverse events (AEs), drug related AEs, drug related AEs leading to dose reduction or discontinuation during treatment period|PART 2: Disease control (DC)|PART 2: Duration of objective response (DoR)|PART 2: Progression-free survival (PFS)|PART 2: Tumour shrinkage (in millimeters)|PART 2: AUC 0-504h (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 504 hours after the first and fourth infusion cycle)|PART 1: Cmax (maximum measured concentration of the analyte in plasma)|PART 1: tmax (time from dosing to maximum measured concentration of the analyte in plasma)|PART 2: Cmax (maximum measured concentration of the analyte in plasma)|PART 2: tmax (time from dosing to maximum measured concentration of the analyte in plasma)","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 1","245","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1336-0011|2017-001378-41","May 3, 2018","August 2, 2021","December 15, 2021","March 16, 2018",,"May 19, 2020","CTR Georges-François Leclerc, Dijon, France|HOP Timone, Marseille Cedex 5, France|INS Curie, Paris, France|CTR Eugène Marquis, Rennes Cedex, France|HOP Nord Laënnec, Saint-Herblain, France|HOP Civil, Strasbourg, France|Universitätsklinikum Augsburg, Augsburg, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03468426"
91,"NCT03086174","Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma",,"Active, not recruiting","No Results Available","Kidney Cancer Stage Iv|Advanced Melanoma","Biological: humanized anti-PD-1 monoclonal antibody Toripalimab","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|PD-1 receptor occupancy of blood|Objective Response Rate (ORR) by irRC and RECIST 1.1|Duration of Response (DOR) by irRC and RECIST 1.1|Disease Control Rate (DCR) by irRC and RECIST 1.1|Time to response (TTR) by irRC and RECIST 1.1|Progression-free survival(PFS) by irRC and RECIST 1.1|Overall survival (OS) by irRC and RECIST 1.1|PK Parameter: Maximum Plasma Concentration (Cmax)|PK Parameter: Peak Time (Tmax)|PK Parameter: t1/2|PK Parameter: Area Under the Curve (AUC)|PK Parameter: Plasma clearance (CL)|PK Parameter: Apparent volume of distribution (V)|PK Parameter: Minimum Plasma Concentration (Cmin)|PK Parameter: Average Plasma Concentration (Cav)|PK Parameter: degree of fluctuation (DF)|PK Parameter: Apparent volume of distribution of steady state (Vss)","Shanghai Junshi Bioscience Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Junshi-JS001-008","March 31, 2017","December 2019","December 2020","March 22, 2017",,"March 11, 2019","Beijing Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03086174"
92,"NCT03728179","RACIN in Patients With Advanced TIL-negative Solid Tumors","RACIN","Recruiting","No Results Available","Solid Tumor, Adult","Combination Product: Low dose irradiation + Nivolumab + Ipilimumab + Aspirin","Phases Ia and Ib: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Maximum Tolerated dose (MTD) or recommended phase Ib dose of low-dose irradiation for radio-immunotherapy combination (RP1bD).|Objective response rate (ORR)|Disease Control Rate (DCR)|Progression free survival (PFS) rate|Time to Progression (TTP):|Overall survival (OS)","Centre Hospitalier Universitaire Vaudois","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUV-DO-0003-RACIN_2017","January 16, 2019","March 15, 2023","March 15, 2023","November 1, 2018",,"March 23, 2020","Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT03728179"
93,"NCT03772561","Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies","MEDIPAC","Recruiting","No Results Available","Solid Tumor, Adult","Drug: AZD5363+Olaparib+Durvalumab","Objective response rate|Best objective response","National University Hospital, Singapore","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC01/01/18|2018/00137","December 3, 2018","December 31, 2021","December 31, 2023","December 11, 2018",,"December 24, 2018","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03772561"
94,"NCT02857166","Study of JS001 in Participants With Advanced Solid Tumors",,"Completed","No Results Available","Solid Tumors","Biological: humanized anti-PD-1 monoclonal antibody toripalimab","Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment|Anti-Drug Antibody of JS001 in Chinese patients|Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-Free survival (PFS)|Overall Survival (OS)|DLT in patients with solid tumor treated with JS001.|PD-1 receptor occupancy of blood|Maximum Plasma Concentration (Cmax) after single dose injection of Anti-PD-1 Monoclonal Antibody (mAb)|Peak Time (Tmax) after single dose injection of Anti-PD-1 mAb|Area Under the Curve (AUC) after single dose injection of Anti-PD-1 mAb Area Under the Curve [AUC]). Area Under the Curve (AUC) after single dose injection of Recombinant Humanized Anti-PD-1 Monoclonal Antibody|t1/2 after single dose injection of Recombinant Humanized Anti-PD-1 mAb|Plasma clearance (CL) after single dose injection of Anti-PD-1 mAb|Apparent volume of distribution (V) after single dose injection of Anti-PD-1 mAb|Minimum Plasma Concentration (Cmin) of steady state after multiple dose injection of Anti-PD-1 mAb|Average Plasma Concentration (Cav) of steady state after multiple dose injection of Anti-PD-1 mAb|Degree of fluctuation (DF) of steady state after multiple dose injection of Anti-PD-1 mAb|Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb","Shanghai Junshi Bioscience Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Junshi-JS001-ZSZL-I","March 2016","September 2017","December 2018","August 5, 2016",,"October 23, 2019","Sun Yat-sen UniversityCancer center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02857166"
95,"NCT03901573","High-Risk Skin Cancers With Atezolizumab Plus NT-I7",,"Recruiting","No Results Available","Melanoma|Merkel Cell Carcinoma|Cutaneous Squamous Cell Carcinoma","Drug: NT-I7|Drug: atezolizumab","Safety and Tolerability of NT-I7 in combination with atezolizumab to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of NT-I7|To evaluate immunogenicity of NT-I7 and atezolizumab|Preliminary assessment of the Objective Response Rate (ORR) of NT-I7 in combination with atezolizumab|Preliminary assessment the Disease Control Rate (DCR) of NT-I7 in combination with atezolizumab|Preliminary assessment the Duration of Objective Response (DOR) of NT-I7 in combination with atezolizumab|Preliminary assessment the Progression Free Survival (PFS) of NT-I7 in combination with atezolizumab|Preliminary assessment the Overall Survival (OS) of NT-I7 in combination with atezolizumab","NeoImmuneTech|Immune Oncology Network","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","84","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIT-106|ION-02","December 26, 2019","February 2024","May 2024","April 3, 2019",,"February 7, 2020","Dana Farber, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mt Sinai, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03901573"
96,"NCT03509584","Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients",,"Not yet recruiting","No Results Available","Non-small Cell Lung Cancer","Radiation: hypofractionated radiotherapy|Drug: nivolumab|Drug: Ipilimumab","Incidence of immune related adverse events","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-21|2017-001198-18","April 2018","April 2020","April 2021","April 26, 2018",,"April 26, 2018","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT03509584"
97,"NCT04198766","Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",,"Recruiting","No Results Available","Solid Tumor|Non-Small Cell Lung Cancer|Melanoma|Head and Neck Cancer|Gastric Cancer|Renal Cell Carcinoma|Urothelial Carcinoma","Drug: INBRX-106 - Hexavalent OX40 agonist antibody|Drug: Pembrolizumab","Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab|Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab|MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab|Area under the serum concentration time curve (AUC) of INBRX-106|Maximum observed serum concentration (Cmax) of INBRX-106|Trough observed serum concentration (Ctrough) of INBRX-106|Time to Cmax (Tmax) of INBRX-106|Immunogenicity of INBRX-106","Inhibrx, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ph 1 INBRX-106","December 10, 2019","December 2, 2022","March 15, 2023","December 13, 2019",,"April 24, 2020","START Midwest, Grand Rapids, Michigan, United States|Providence Cancer Institute, Portland, Oregon, United States|NEXT Oncoloy, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04198766"
98,"NCT03167853","Study of JS001 in Patients With Advanced Neuroendocrine Tumors",,"Completed","No Results Available","Neuroendocrine Tumors","Biological: humanized anti-PD-1 monoclonal antibody","Overall response rate (ORR)|Duration of response (DOR)|Progression-free survival|Overall survival|Immune Response Criteria by irRECIST (immune response duration of response)|Immune Response Criteria by irRECIST (immune response overall response rate)|Biochemical response|Correlation analysis of PD-L1/CD8 expression of tumor and ORR|Correlation analysis of circulating tumor cells (CTC) and ORR","Peking University|Shanghai Junshi Biosciencee Co.,Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HMO-JS001-Ib-NEC-02","April 6, 2017","December 11, 2018","May 11, 2019","May 30, 2017",,"June 21, 2019","Beijing Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03167853"
99,"NCT04379596","Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)","DG-03","Not yet recruiting","No Results Available","Gastric Cancer","Drug: Fluorouracil (5-FU)|Drug: Capecitabine|Biological: Durvalumab|Drug: Oxaliplatin|Biological: Trastuzumab|Drug: Trastuzumab deruxtecan|Drug: Cisplatin","Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs)|Part 2: Objective Response Rate (ORR)|Part 1: Objective Response Rate (ORR)|Part 2: Occurrence of adverse events (AEs) and serious adverse events (SAEs)|Duration of Response (DoR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall survival (OS)|Serum concentration of T-DXd, total anti-HER2 antibody, and MAAA-1181a in all arms|Serum concentration of durvalumab in study arms including T-DXd in combination with durvalumab|Presence of ADAs for T-DXd and durvalumab (in study arms including T-DXd and durvalumab)","AstraZeneca|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 1|Phase 2","220","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D967LC00001","May 25, 2020","December 27, 2022","December 27, 2022","May 7, 2020",,"May 7, 2020","Research Site, New York, New York, United States|Research Site, Toronto, Ontario, Canada|Research Site, Berlin, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Verona, Italy|Research Site, Seongnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Madrid, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04379596"
100,"NCT03879057","Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors",,"Recruiting","No Results Available","Solid Tumor","Drug: Surufatinib/humanized anti-PD-1 monoclonal antibody","adverse events|Maximum tolerated dose|Objective response rate|time to treatment failure(TTF)|Maximum Plasma Concentration (Cmax)|Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))","Peking University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CGOG-3006/2018-012-00CH2","December 21, 2018","December 20, 2020","December 20, 2021","March 18, 2019",,"October 1, 2019","Beijing Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03879057"
101,"NCT01115790","A Phase 1 Study in Participants With Advanced Cancer",,"Completed","No Results Available","Advanced Cancer|Squamous Cell Carcinoma|Carcinoma, Squamous Cell of Head and Neck|Lung Squamous Cell Carcinoma Stage IV|Anal Squamous Cell Carcinoma|Carcinoma, Non-Small-Cell Lung","Drug: Prexasertib","Determination of a Recommended Phase 2 Dosing Regimen: Maximum Tolerated Dose (Parts A and B)|Determination of Clinically Significant Safety Effects (Parts A and B)|Percentage of Participants With a Complete or Partial Response (Overall Response Rate) (Part C)|Percentage of Participants with Complete Response, Partial Response, or Stable Disease (Disease Control Rate) (Parts A, B, and C)|Progression Free Survival (Parts B and C)|Duration of Response (Parts B and C)|Preliminary Pharmacokinetics of Prexasertib (Cmax) (Parts A, B, and C)|Preliminary Pharmacokinetics of Prexasertib (AUC) (Parts A, B, and C)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1","150","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13129|I4D-MC-JTJA","February 2010","January 2016","January 2016","May 4, 2010",,"May 10, 2016","Florida Cancer Specialists, Sarasota, Florida, United States|Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01115790"
102,"NCT04101357","Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411",,"Not yet recruiting","No Results Available","Solid Tumor|Extensive-stage Small Cell Lung Cancer","Drug: BNT411|Drug: Atezolizumab|Drug: Carboplatin|Drug: Etoposide","Incidence of DLTs|Incidence of TEAEs|Incidence of IMP dose reductions|Incidence of IMP treatment discontinuations due to toxicity|Maximum Plasma Concentration (Cmax) of PK assessments|Area under the curve (AUC) of PK assessments|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DOR)","BioNTech Small Molecules GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BNT411-01","June 2020","June 2022","December 2023","September 24, 2019",,"November 15, 2019",,,"https://ClinicalTrials.gov/show/NCT04101357"
103,"NCT02890069","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",,"Recruiting","No Results Available","Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma","Biological: PDR001|Drug: LCL161|Drug: Everolimus|Drug: Panobinostat|Drug: QBM076|Drug: HDM201","Phase 1: Incidence of dose limiting toxicities (DLTs)|Frequency of dose interruptions and reductions|Frequency and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)|Changes between baseline and post-baseline laboratory parameters and vital signs|Dose intensities|Quantification of Tumor Infiltrating Lymphocytes (TILs) by Hematoxylin|Changes from baseline in ECG parameters in patients recieving PDR001 in combination with Panobinostat|Best overall response (BOR)|Time to reach max concentration (Tmax) for PDR001|Presence of anti-PDR001 antibodies|Progression free survival (PFS)|Treatment Free Survival (TFS)|Maximum and minimum plasma concentrations of LCL161 (Cmax and Cmin)|Maximum and minimum Plasma concentrations of everolimus (Cmax and Cmin)|Maximum and minimum plasma concentrations of panobinostat (Cmax and Cmin)|Concentration of anti-PDR001 antibodies|Characterization of TILs and myeloid cell infiltrate by IHC (such as CD8, FoxP3 and myeloid markers as appropriate)|Quantification of Tumor Infiltrating Lymphocytes (TILs) by eosin (H&E) stain|Maximum and minimum serum concentration of PDR001 (Cmax and Cmin)|Area under the concentration-time curve calculated to the last concentration point (AUClast) for PDR001, as applicable|Progression free survival (PFS) per irRC|Area under the concentration-time curve calculated to the last concentration point (AUClast) for LCL161, as applicable|Time to reach max concentration (Tmax) for LCL161|Time to reach max concentration (Tmax) for Everolimus|Time to reach max concentration (Tmax) for Panobinostat|Area under the concentration-time curve calculated to the last concentration point (AUClast) for Everolimus, as applicable|Area under the concentration-time curve calculated to the last concentration point (AUClast) for Panobinostat, as applicable|Maximum and minimum Plasma concentrations of QBM076 (Cmax and Cmin)|Maximum and minimum Plasma concentrations of HDM201 (Cmax and Cmin)|Time to reach max concentration (Tmax) for QBM076|Time to reach max concentration (Tmax) for HDM201|Area under the concentration-time curve calculated to the last concentration point (AUClast) for QBM076, as applicable|Area under the concentration-time curve calculated to the last concentration point (AUClast) for HDM201, as applicable","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","315","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPDR001X2102","October 14, 2016","May 28, 2021","May 28, 2021","September 7, 2016",,"April 21, 2020","Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02890069"
104,"NCT04185311","Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted",,"Recruiting","No Results Available","Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|HER2/Neu Negative|Invasive Ductal Carcinoma, Not Otherwise Specified|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma","Biological: Ipilimumab|Biological: Nivolumab|Biological: Talimogene Laherparepvec","Incidence and severity of adverse events (AEs)|histopathological evaluation of changes of tumor for inflammatory infiltration and tumor necrosis","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-000427|NCI-2018-01410|Glaspy BMS CA209-9ET Breast|P30CA016042","July 10, 2019","July 1, 2020","July 1, 2021","December 4, 2019",,"December 4, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04185311"
105,"NCT01963052","ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer",,"Completed","No Results Available","Metastatic Urothelial Cancer","Drug: AGS15E","Incidence of adverse events|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Concentration at the end of infusion (CEOI)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Trough concentration (Ctrough)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-7)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Terminal or apparent terminal half-life (t1/2)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Systemic clearance (CL)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Volume of distribution at steady state (Vss)|Incidence of Anti-Drug Antibody (ADA)|Tumor response|Objective response rate|Disease control rate|Progression free survival|Duration of response","Astellas Pharma Global Development, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 1","93","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGS15E-13-1","November 14, 2013","July 8, 2019","July 8, 2019","October 16, 2013",,"November 25, 2019","Site US00006, Birmingham, Alabama, United States|Site US00002, New Haven, Connecticut, United States|Site US00001, Detroit, Michigan, United States|Site US00003, Saint Louis, Missouri, United States|Site US00009, Buffalo, New York, United States|Site US00011, Pittsburgh, Pennsylvania, United States|Site US00010, Nashville, Tennessee, United States|Site US00008, Seattle, Washington, United States|Site CA00004, Vancouver, British Columbia, Canada|Site CA00007, Hamilton, Ontario, Canada|Site CA00005, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01963052"
106,"NCT02403193","Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","AdenONCO","Recruiting","No Results Available","Non-small Cell Lung Cancer (NSCLC)","Drug: PBF-509_80 mg|Drug: PBF-509_160 mg|Drug: PBF-509_320 mg|Drug: PBF-509_640 mg|Drug: Combo PBF-509 (160 mg) + PDR001|Drug: Combo PBF-509 (320 mg) + PDR001|Drug: Combo PBF-509 (640 mg) + PDR001|Drug: RP2D (PBF-509+PDR001)_immuno naïve|Drug: Experimental: RP2D (PBF-509+PDR001)_immuno treated","Maximum Tolerated Dose (MTD) of PBF-509 as single agent|Maximum Tolerated Dose (MTD) of the combination (PBF-509+PDR001) treatment|Time to PBF-509 peak concentration in plasma ""Tmax""|Time to PBF-509 peak concentration in plasma at steady state ""Tmax,ss""|PBF-509 peak concentration in plasma ""Cmax""|PBF-509 peak concentration in plasma at steady state""Cmax,ss""|The area under PBF-509 plasma concentration-time curve to infinite time ""AUC(0-inf)""|The area under PBF-509 plasma concentration-time curve up to time 't' ""AUC(0-t)""|The area under PBF-509 plasma concentration-time curve over the dosing interval ""AUC(0-τ)""|PBF-509 half-life in plasma "" t½""|PBF-509 apparent volume of distribution following extravascular administration""Vd/F""|PBF-509 total body clearance following extravascular administration ""Cl/F""|The PBF 509 accumulation index ""Rac""|Efficacy as measured by Objective response rate (ORR)|Efficacy as measured by Disease control rate (DCR)|Efficacy as measured by duration of response (DoR)|Efficacy as measured by progression-free survival (PFS)|Efficacy as measured by overall survival (OS)","Palobiofarma SL|Novartis|H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","92","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC18321","October 2015","October 2020","December 2020","March 31, 2015",,"November 6, 2018","H.Lee Moffitt Cancer center, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02403193"
107,"NCT03667716","COM701 in Subjects With Advanced Solid Tumors",,"Recruiting","No Results Available","Advanced Cancer|Ovarian Cancer|Breast Cancer|Lung Cancer|Endometrial Cancer|Ovarian Neoplasm|Triple Negative Breast Cancer|Lung Neoplasm|Neoplasm Malignant|Colo-rectal Cancer","Drug: COM701|Drug: COM701 with Opdivo (Nivolumab).","Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs).|Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with a PD-1 inhibitor).|Incidence of subjects with Anti-COM701 antibody.|Overall Response Rate as per RECIST v1.1","Compugen Ltd|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","140","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPG-01-001","September 6, 2018","June 2021","December 2021","September 12, 2018",,"January 31, 2020","University of California Los Angeles (UCLA)., Los Angeles, California, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|START Midwest., Grand Rapids, Michigan, United States|Columbia University, New York, New York, United States|Cleveland Clinic., Cleveland, Ohio, United States|The University of Tennessee WEST Cancer Center., Memphis, Tennessee, United States|Sarah Cannon Research Institute., Nashville, Tennessee, United States|M D Anderson Cancer Center., Houston, Texas, United States|The START Center for Cancer Care., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03667716"
108,"NCT03322384","UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma",,"Recruiting","No Results Available","Advanced Solid Tumors|Lymphoma","Drug: epacadostat|Drug: SD-101|Radiation: Radiotherapy","Maximum tolerated dose (MTD)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Abscopal Response Rate","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1057229|UCDCC#271","January 17, 2018","October 1, 2020","October 1, 2021","October 26, 2017",,"March 25, 2019","University of California Davis Comprehensive Cancer Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03322384"
109,"NCT02926768","Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors",,"Active, not recruiting","No Results Available","Lung Neoplasms|Carcinoma, Non-Small-Cell Lung|Lung Diseases|Adenocarcinoma","Drug: CK-101","Phase I: Incidence of dose-limiting toxicities (DLTs)|Phase II: Objective response rate (ORR): Defined as the rate of complete responses [CR] or partial responses [PR] per RECIST Version 1.1 as assessed by an independent central review|Phase II: Evaluation of tumor response based on disease control rate as assessed by RECIST 1.1|Phase II: Evaluation of tumor response based on duration of response as assessed by RECIST 1.1|Phase II: Evaluation of tumor response based on tumor shrinkage as assessed by RECIST 1.1|Phase II: Evaluation of tumor response based on progression free survival as assessed by RECIST 1.1|Phase I: Change from baseline in QT/QTc interval|Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by area under the curve|Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by maximum concentration|Phase I: Plasma concentrations of CK-101 following dosing with CK-101 as assessed by elimination half-life","Checkpoint Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","136","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CK-101-101","September 2016","June 2020","December 2020","October 6, 2016",,"January 22, 2020","Research Site, Sarasota, Florida, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Nashville, Tennessee, United States|Research Site, Greenslopes, Queensland, Australia|Research Site, Grafton, Auckland, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Wellington, New Zealand|Research Site, Bydgoszcz, Kujawsko-Pomorskie, Poland|Research Site, Bydgoszcz, Kujawsko-Pomorskie, Poland|Research Site, Lublin, Lubelskie, Poland|Research Site, Białystok, Podlaskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Szczecin, Zachodniopomorskie, Poland|Research Site, Pathumwan, Bangkok, Thailand|Research Site, Ratchathewi District, Bangkok, Thailand|Research Site, Bangkok Noi District, Bangkok, Thailand|Research Site, Muang District, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang, Phitsanulok, Thailand",,"https://ClinicalTrials.gov/show/NCT02926768"
110,"NCT03057340","The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells",,"Not yet recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Biological: Dribble vaccine","Progression free survival|Safety: to evaluate the overall safety of allogeneic NSCLC DRibble vaccine alone or in combination with either imiquimod or GM-CSF","Second Affiliated Hospital, School of Medicine, Zhejiang University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","pl001","June 1, 2017","December 1, 2019","December 1, 2020","February 20, 2017",,"February 20, 2017",,,"https://ClinicalTrials.gov/show/NCT03057340"
111,"NCT03696212","Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma",,"Recruiting","No Results Available","Non-small Cell Lung Cancer Adenocarcinoma","Drug: grapiprant and pembrolizumab","Safety and tolerability of grapiprant in combination with pembrolizumab|Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab|Objective response rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)|Duration of treatment (DoT)|Disease control rate (DCR)|Duration of response (DoR)|PK of grapiprant: AUC|PK of grapiprant: Cmax|Plasma decay half-life (t1/2)|Apparent oral clearance (CL/F)|Peak to trough ratio|Observed accumulation ratio|Pharmacodynamic immune effects in paired tumor biopsies","Arrys Therapeutics|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARYS-002","January 8, 2019","September 2020","September 2020","October 4, 2018",,"April 5, 2019","Stanford University Medical Center, Stanford, California, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03696212"
112,"NCT03554473","M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers",,"Recruiting","No Results Available","Carcinoma, Small Cell|Lung Cancer|Small Cell Lung Cancer","Drug: M7824|Drug: Topotecan|Drug: Temozolomide","Efficacy|Safety|PFS, DOR and OS","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","67","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180110|18-C-0110","September 11, 2018","January 15, 2023","January 15, 2024","June 13, 2018",,"April 24, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03554473"
113,"NCT03425461","Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma",,"Recruiting","No Results Available","Metastatic Melanoma|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7","Biological: Anti-SEMA4D Monoclonal Antibody VX15/2503|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study","Maximum tolerated dose of anti-SEMA4D monoclonal antibody VX15/2503 determined by dose limiting toxicity assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Antitumor activity assessed using tumor response|Duration of response|Frequency of tumor measurements|Incidence of adverse events based on the Common Toxicity Criteria version 4.0|Response for in-transit metastasis","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-001570|NCI-2017-02395|P30CA016042","June 14, 2018","December 1, 2020","December 1, 2021","February 7, 2018",,"December 12, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03425461"
114,"NCT04290546","CIML NK Cell in Head & Neck Cancer",,"Not yet recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck|Recurrent Head and Neck Squamous Cell Carcinoma","Drug: Interleukin-15 Superagonist (N-803)|Biological: CIML NK cell Infusion|Drug: Ipilimumab","Rate of Dose Limiting Toxicity|objective response rate (ORR)|complete response (CR) rate|disease-free survival (DFS)|overall survival (OS) at 1-year following infusion","Dana-Farber Cancer Institute|Altor BioScience|Bristol-Myers Squibb|Miltenyi Biotec B.V. & Co. KG","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-505","March 2020","September 30, 2021","September 30, 2022","March 2, 2020",,"March 2, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04290546"
115,"NCT04072900","A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma",,"Recruiting","No Results Available","Melanoma (Skin)","Drug: Peptide|Drug: Anti-PD-1|Drug: rhGM-CSF|Drug: Imiquimod 5% Topical Cream","Number of participants experiencing adverse events|Number of Patients with Complete Remission Rate|Number of Patients with Progressive Disease|Number of Patients with Partial Response|Monitoring of cellular immune response","Xiangya Hospital of Central South University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XYM001","April 21, 2020","September 1, 2021","September 1, 2022","August 28, 2019",,"April 28, 2020","Xiangya Hospital, Central South University, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT04072900"
116,"NCT03164772","Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC",,"Recruiting","No Results Available","Metastatic Non-small Cell Lung Cancer|NSCLC","Drug: Durvalumab|Drug: Tremelimumab|Biological: BI 1361849","Number of Adverse Events|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Duration of Response (DoR)|Overall Survival (OS)","Ludwig Institute for Cancer Research|Cancer Research Institute, New York City|Boehringer Ingelheim|MedImmune LLC|CureVac AG|PharmaJet, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","56","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LUD2014-012-VAC","December 20, 2017","March 2021","December 2024","May 24, 2017",,"March 10, 2020","Research Facility, Gilbert, Arizona, United States|Research Facility, Tampa, Florida, United States|Research Facility, Detroit, Michigan, United States|Research Facility, New York, New York, United States|Research Facility, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03164772"
117,"NCT04212221","MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients",,"Recruiting","No Results Available","Advanced Hepatocellular Carcinoma (HCC)","Drug: MGD013 monotherapy|Drug: MGD013 in combination with Brivanib Alaninate","Dose-limiting toxicities (DLTs)|Adverse Events Assessed by CTCAE Criteria|Objective response rate (ORR)|Disease control rate (DCR)|Time to tumor progression (TTP)|Duration of response (DoR)|Progression-free survival (PFS)|Overall survival (OS)","Zai Lab (Shanghai) Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZL-MGD013-202","April 20, 2020","December 2022","June 2023","December 26, 2019",,"April 24, 2020","Prince of Wales Hospital, Hong Kong, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT04212221"
118,"NCT04301011","Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors","RAPTOR","Not yet recruiting","No Results Available","Solid Tumor|Triple Negative Breast Cancer|Microsatellite Stable Colorectal Cancer","Biological: TBio-6517|Biological: Pembrolizumab","Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) alone at each dose level|Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) when combined with pembrolizumab|Maximum tolerated dose (MTD) or Maximum feasible dose (MFD) and determination of the recommended Phase 2 dose (RP2D) of TBio-6517 alone and in combination with pembrolizumab.|Percentage of overall response rate (ORR) by RECIST 1.1 at the RP2D|Percentage of overall response rate (ORR) by immunotherapy RECIST (iRECIST) at the RP2D|Number and severity of adverse events at the RP2D|Median overall survival (OS)|Median Duration of Response (DoR)|Proportion of patients with a response (ORR)|Median Disease Control Rate (DCR)|Time to tumor progression (TTP)|Median progression free survival","Turnstone Biologics, Corp.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","84","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBio-6517-ITu-001","April 20, 2020","August 20, 2022","December 30, 2022","March 9, 2020",,"March 9, 2020","Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center / UMHC, Miami, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|The Billings Clinic, Billings, Montana, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04301011"
119,"NCT02040064","Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients","GEFTREM","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Gefitinib|Drug: Tremelimumab","safety and tolerability of the association between Gefitinib (fixed dose) and Tremelimumab (dose escalation)|Anti-tumour activity of Gefitinib + Tremelimumab|Immunogenicity of Tremelimumab in combination with Gefitinib|Pharmacokinetics of Gefitinib|Pharmacokinetics of Tremelimumab","Gustave Roussy, Cancer Campus, Grand Paris|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-003015-21|2013/2028","January 2014","March 2016","March 2016","January 20, 2014",,"June 9, 2016","Gustave Roussy, Villejuif, Val de Marne, France",,"https://ClinicalTrials.gov/show/NCT02040064"
120,"NCT03385486","Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors",,"Recruiting","No Results Available","Stage III Melanoma|Stage IV Melanoma","Biological: TBX-3400","Incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Tumor responses as defined by RECIST version 1.1|Tumor responses as defined by irRECIST|Assessment of concentrations of certain chemokines, such as cluster of differentiation 69 (CD69), as biomarkers of activity of TBX-3400|Presence and/or concentration of anti TBX-3400 antibodies","Taiga Biotechnologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBX-3400-001","June 2, 2019","April 2022","April 2022","December 28, 2017",,"September 19, 2019","University of Colorado Cancer Center, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03385486"
121,"NCT03281369","A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)",,"Recruiting","No Results Available","Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","Drug: 5-Fluorouracil (5-FU)|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Atezolizumab|Drug: Cobimetinib|Biological: Ramucirumab|Drug: Paclitaxel|Biological: PEGylated recombinant human hyaluronidase (PEGPH20)|Drug: BL-8040|Drug: Linagliptin|Drug: Cisplatin|Drug: Tiragolumab","Percentage of Participants With Objective Response, as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)|Percentage of Participants with Adverse Events (AEs)|For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs|Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1|Overall Survival (OS)|Percentage of Participants Who Are Alive at Month 6 and at Month 12|Duration of Response, as Determined by Investigator According to RECIST v1.1|Percentage of Participants With Disease Control, as Determined by the Investigator per RECIST v1.1|Serum Concentration of Atezolizumab|Plasma Concentration of Cobimetinib|Plasma Concentration of PEGPH20|Plasma Concentration of BL-8040|Plasma Concentration of Linagliptin|Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab|Percentage of Participants With ADA to PEGPH20|Percentage of Participants With ADA to BL-8040|Percentage of Participants With Objective Response, in Participants with TIGIT-Positive Tumors by IHC (Esophageal Cancer Cohort Only)|Percentage of Participants With Objective Response, in Participants With PD-L1 IC/TC-Positive Tumors by IHC (Esophageal Cancer Cohort Only)","Hoffmann-La Roche|Halozyme Therapeutics|BioLineRx, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","410","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YO39609|2016-004529-17","October 13, 2017","November 13, 2021","November 13, 2021","September 13, 2017",,"May 20, 2020","Mayo Clinic Cancer Center, Scottsdale, Arizona, United States|Uni of Southern California; Norris Comprehensive Cancer Ctr, Los Angeles, California, United States|Dana-Farber Cancer Institute - Gastrointestinal Cancer Treatment Center, Boston, Massachusetts, United States|Mayo Clinic - Rochester; Breast Cancer Center, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Gustave Roussy Cancer Campus, Villejuif, France|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF), Frankfurt am Main, Germany|Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany|Seoul National University Hospital (SNUH) - Medical Oncology Center, Jongno -Gu, Korea, Republic of|Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center; Cancer Metastasis Research Center, Seodaemun-Gu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC), Songpa-gu, Korea, Republic of|The Catholic University of Korea St. Vincent's Hospital, Suwon-si,, Korea, Republic of|Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Universidad de Navarra - Clinica Universitaria de Navarra (CUN), Pamplona, Navarra, Spain|Hospital Universitari Vall dHebron; Oncology, Barcelona, Spain|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital (NTUH) - Cancer Research Center, Zhongzheng Dist., Taiwan|The Royal Marsden, London, United Kingdom|The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03281369"
122,"NCT03959761","Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma","ICONIC","Not yet recruiting","No Results Available","Ovarian Cancer","Drug: Intraperitoneal (IP) nivolumab infusion","Safety profile of the Intraperitoneal (IP) nivolumab treatment|Changes over time in disease progression|Changes in toxicity as assessed by the Common Terminology Criteria (CTC) scale- Surgery|Changes over time in toxicity as assessed by the Common Terminology Criteria (CTC) scale- Intraperitoneal (IP) nivlumab infusion|Changes in tolerance of post procedure intravenous (IV) chemotherapy- Surgery|Changes over time in tolerance of post procedure intravenous (IV) chemotherapy- Intraperitoneal (IP) nivlumab infusion","Hospices Civils de Lyon","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","32","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","69HCL18_0802|2018-004408-21","July 31, 2019","January 31, 2021","November 30, 2021","May 22, 2019",,"May 24, 2019","Hospices Civils de Lyon, Lyon, France",,"https://ClinicalTrials.gov/show/NCT03959761"
123,"NCT04037462","Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy",,"Not yet recruiting","No Results Available","Non-Small Cell Lung Cancer|Immunotherapy","Drug: Dexamthasone","Reduction in FLT-PET signal|Response rate","VA Office of Research and Development|Wayne State University|University of Michigan|Barbara Ann Karmanos Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","U.S. Fed|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSDR-002-18F","August 1, 2020","July 31, 2022","April 1, 2024","July 30, 2019",,"May 11, 2020","VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04037462"
124,"NCT03337698","A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","Morpheus Lung","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Atezolizumab|Drug: Cobimetinib|Drug: RO6958688|Drug: Docetaxel|Drug: CPI-444|Drug: Pemetrexed|Drug: Carboplatin|Drug: Gemcitabine|Drug: Linagliptin|Drug: Tocilizumab|Drug: Ipatasertib|Drug: Idasanutlin|Drug: Bevacizumab","Percentage of Participants with Objective Response|Progression Free Survival (PFS)|Overall Survival After Randomization|Percentage of Participants Who Are Alive at Month 6 and at Month 12|Duration of Response|Disease Control|Percentage of Participants with Adverse Events","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO39610|2017-001267-21","January 2, 2018","February 1, 2022","April 16, 2022","November 9, 2017",,"March 17, 2020","Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Peter Mac Callum Cancer Center, East Melbourne, Victoria, Australia|Centre Léon Bérard, Lyon, France|Hopital de la Timone, Marseille, France|Institut Universitaire du Cancer de Toulouse-Oncopole; PHARMACIE, Toulouse, France|Rambam Medical Center; Oncology, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC), Songpa-gu, Korea, Republic of|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Fundación Jimenez Díaz, Madrid, Spain|South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro, Madrid, Spain|Barts Cancer Institute, London, United Kingdom|Royal Marsden Hospital; Institute of Cancer Research, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03337698"
125,"NCT03576612","GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas","GMCI","Recruiting","No Results Available","Glioma, Malignant","Biological: AdV-tk|Drug: Valacyclovir|Radiation: Radiation|Drug: Temozolomide|Biological: Nivolumab|Other: Laboratory Biomarker Analysis","Incidence of adverse events|Overall survival (death)|Progression-free survival (progression)|Immune profiling - Tumor Tissue|Tumor mutation - Tumor Tissue|Peripheral blood mononuclear cells (PBMCs) in serum samples|Immune characterization as determined by Cytokines|Immune characterization as determined by Extracellular vesicles (EVs) proteins","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Advantagene, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABTC-1603|IRB00172749|UM1CA137443","February 27, 2018","February 28, 2021","February 28, 2021","July 3, 2018",,"May 20, 2020","University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03576612"
126,"NCT02073123","Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma",,"Active, not recruiting","No Results Available","Metastatic Melanoma|Stage III Melanoma|Stage IV Melanoma","Drug: Indoximod|Drug: Ipilimumab|Drug: Nivolumab|Drug: Pembrolizumab","Overall Incidence of Adverse Events as a Measure of Safety and Tolerability|Phase 2 Dosing|Overall Response Rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Survival|Mechanisms of activity/resistance to IDO/CTLA-4 inhibitor therapy|Progression Free Survival|Disease control rate","NewLink Genetics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","132","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG2103","July 2014","January 17, 2018","June 13, 2019","February 27, 2014",,"April 25, 2019","Augusta University, Augusta, Georgia, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|New Mexico Cancer Center Alliance, Albuquerque, New Mexico, United States|Penn State Hershey Cancer Institue, Hershey, Pennsylvania, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02073123"
127,"NCT03678883","9-ING-41 in Patients With Advanced Cancers",,"Recruiting","No Results Available","Cancer|Lymphoma|Pancreatic Cancer|Glioblastoma Multiforme|Sarcoma|Breast Cancer|Bladder Cancer|Renal Cancer|Ovarian Cancer|Refractory Cancer|Refractory Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Brain Tumor|Pancreatic Adenocarcinoma|Resistant Cancer|Neoplasm Metastasis|Neoplasm of Bone|Neoplasm, Breast|Neoplasm of Lung|Neoplasms,Colorectal|Neoplasms Pancreatic|Malignant Glioma|Malignancies|Malignancies Multiple|Bone Metastases|Bone Neoplasm|Bone Cancer|Pancreas Cancer|Pancreatic Neoplasms|Breast Neoplasms","Drug: 9-ING-41|Drug: Gemcitabine - 21 day cycle|Drug: Doxorubicin.|Drug: Lomustine|Drug: Carboplatin.|Drug: Nab paclitaxel.|Drug: Paclitaxel.|Drug: Gemcitabine - 28 day cycle|Drug: Irinotecan","Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03","Actuate Therapeutics Inc.|Developmental Therapeutics Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","350","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1801","January 4, 2019","November 2022","November 2022","September 20, 2018",,"May 28, 2020","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Miami Cancer Institute, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|Kansas University Cancer Center, Kansas City, Kansas, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Sanford Research, Sioux Falls, South Dakota, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Netherlands Cancer Institute, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03678883"
128,"NCT03332498","Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers",,"Active, not recruiting","No Results Available","Colon Cancer|Colorectal Cancer|Colorectal Carcinoma|Colon Disease","Drug: Pembrolizumab|Drug: Ibrutinib","Phase I - Recommended Phase II Dose (RP2D)|Phase II - Disease Control Rate at 4 Months","H. Lee Moffitt Cancer Center and Research Institute|Janssen Scientific Affairs, LLC|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-19091","January 24, 2018","February 2021","February 2022","November 6, 2017",,"February 6, 2020","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03332498"
129,"NCT02797977","A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer",,"Active, not recruiting","No Results Available","Advanced Solid Tumors","Drug: SRA737, gemcitabine, cisplatin|Drug: SRA737, gemcitabine","Number of subjects with adverse events as assessed by CTCAE4.03|Maximum tolerated dose of SRA737 administered in combination with gemcitabine|Recommended Phase 2 dose of SRA737 in combination with gemcitabine.","Sierra Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","153","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRA737-02","July 2016","January 2020","March 2020","June 14, 2016",,"January 3, 2020","Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|START Madrid, Madrid, Spain|Hospital Universitario 12 de Octobre, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Biomedical Research Institute INCLIVA, Valencia, Spain|Royal Marsden Hospital, Sutton, London, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Oxford University Hospitals, Headington, Oxford, United Kingdom|Velindre Cancer Centre, Cardiff, Whitchurch, United Kingdom|The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Leeds Teaching Hospital of St James University Hospital, Leeds, United Kingdom|University Hospital of Leceister NHS TRUST, Leicester, United Kingdom|Guy's and St Thomas', London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|University College London, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02797977"
130,"NCT02936102","A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",,"Active, not recruiting","No Results Available","Advanced Solid Tumors|Triple Negative Breast Cancer|Chordoma and Alveolar Soft Part Sarcoma","Drug: FAZ053|Drug: PDR001","Number of participants with Adverse Events (AEs) as a measure of safety and tolerability|Serum concentration-time profiles of FAZ053 as single agent and FAZ053 in combination with PDR001.|Presence of anti-FAZ053 and anti-PDR001.|Concentration of anti-FAZ053 and anti-PDR001.|Receptor Occupancy (RO) profiles when FAZ053 is given as single agent.|Total soluble/shed PD-L1 concentration-time profiles when FAZ053 is given as single agent and for FAZ053 in combination with PDR001.|Histopathology of tumor infiltrating lymphocytes (TILs) by hematoxylin.|Histopathology of tumor infiltrating lymphocytes (TILs) by eosin (H&E) stain.|Overall response rate (ORR) per RECIST v1.1|Best overall response per RECIST v1.1|Disease control rate per RECIST 1.1|Progression free survival (PFS) per RECIST 1.1|Duration of response per RECIST 1.1|Overall response rate (ORR) per immune related Response Criteria (irRC).|Progression free survival (PFS) per immune related Response Criteria (irRC).|Characterization of Tumor Infiltrating Lymphocytes (TILs) by Immunohistochemistry (IHC)|Characterization of myeloid cell infiltrate by IHC.|Area under the curve (AUC) for FAZ053 as single agent and FAZ053 in combination with PDR001.|Cmax for FAZ053 as single agent and FAZ053 in combination with PDR001.|Tmax for FAZ053 as single agent and FAZ053 in combination with PDR001.|Half-life for FAZ053 as single agent and FAZ053 in combination with PDR001.|Clast for FAZ053 as single agent and FAZ053 in combination with PDR001.|Tlast for FAZ053 as single agent and FAZ053 in combination with PDR001.","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","154","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CFAZ053X2101|2016-001470-15","October 20, 2016","November 30, 2020","November 30, 2020","October 18, 2016",,"January 21, 2020","Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Koto ku, Tokyo, Japan|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02936102"
131,"NCT03633110","Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",,"Active, not recruiting","No Results Available","Cutaneous Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Urothelial Carcinoma|Renal Cell Carcinoma","Biological: GEN-009 Adjuvanted Vaccine|Drug: Nivolumab|Drug: Pembrolizumab","Incidence of Treatment-Emergent Adverse Events|T-cell responses to GEN-009 adjuvanted vaccine|Antitumor activity of GEN-009 in Part B","Genocea Biosciences, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","99","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEN-009-101","August 29, 2018","December 2022","December 2022","August 16, 2018",,"May 6, 2020","UC San Diego Moores Cancer Center, La Jolla, California, United States|John Wayne Cancer Institute - Providence Saint John's Health Center, Santa Monica, California, United States|University of Colorado, Anschutz Cancer Pavilion, Aurora, Colorado, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03633110"
132,"NCT03906526","A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer",,"Recruiting","No Results Available","Carcinoma, Squamous Cell","Drug: VTX-2337|Drug: Nivolumab","Numbers of CD8+ T cells within the tumor pre-treatment and post-surgery|Number of Patients With adverse events that lead to delay in resection|Evaluation of safety and tolerability of nivolumab, motolimod and the combination of nivolumab with motolimod","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VTX-2337-HN-001|U1111-1223-3488","July 3, 2019","December 31, 2020","January 25, 2021","April 8, 2019",,"April 7, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|Boston University, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of North Carolina, Chapel Hill, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Sanford Cancer Center, Sioux Falls, South Dakota, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03906526"
133,"NCT02690948","Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer",,"Completed","Has Results","Skin Basal Cell Carcinoma","Biological: Pembrolizumab|Drug: Vismodegib","Overall Response Rate (ORR)|Percentage of Participants Experiencing Adverse Events|Related Adverse Events|Duration of Response (DOR)|Overall Survival (OS)|Progression-free Survival (PFS)","Anne Chang|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","16","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-34925|NCI-2015-01869|350|P30CA124435|SKIN0031","February 1, 2016","November 30, 2017","August 29, 2018","February 24, 2016","March 8, 2019","March 8, 2019","Stanford University School of Medicine, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02690948/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02690948"
134,"NCT04034225","Addition of SNS-301 to Ongoing Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN",,"Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: SNS-301|Drug: Pembrolizumab","Adverse events of SNS-301 in addition to pembrolizumab|Objective response rate by RECIST and iRECIST|Duration of response by RECIST 1.1 and iRECIST|Disease control rate by RECIST 1.1 and iRECIST|Progression free survival by RECIST 1.1 and iRECIST|Overall survival|Antigen-specific response|T cell and B cell activation response|Myeloid derived suppressor cell analysis|TCR sequencing|Immune gene transcript profiling|Profiling of pro-inflammatory/immunosuppressive molecules","Sensei Biotherapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNS-301-2-2","November 11, 2019","February 1, 2021","February 1, 2022","July 26, 2019",,"May 26, 2020","University of California - San Francisco, San Francisco, California, United States|Christiana Care, Newark, Delaware, United States|Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Rush University, Chicago, Illinois, United States|Washington University, Saint Louis, Missouri, United States|Mt. Sinai, New York, New York, United States|New Orleans Clinical Research, Knoxville, Tennessee, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04034225"
135,"NCT02718820","Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer",,"Active, not recruiting","No Results Available","Head and Neck Carcinoma","Drug: Docetaxel|Drug: Pembrolizumab","Overall response rate|Best overall response categories i.e. complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) given in percentages of the total study population|Individual duration of response over time|To report changes in the in health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) C-30 scoring manual|To report changes in the in health-related quality-of-life scores per patient measured according to the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) H&N35 scoring manual|Median Overall Survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Median Progression Free Survival (PFS)","Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PemDoc II","March 2016","August 2020","August 2020","March 24, 2016",,"February 7, 2020","Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02718820"
136,"NCT03966209","Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant",,"Recruiting","No Results Available","Hepatocellular Carcinoma|Liver Transplantation","Drug: JS001(PD-1 inhibitor)","Serious Adverse Event Rate|Acute Graft Rejection Rate|Objective Response Rate|Progression Free Survival Rate|Over all survival Rate","Shanghai Zhongshan Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JS001LT","May 1, 2019","April 30, 2021","October 31, 2022","May 29, 2019",,"May 31, 2019","Shanghai Zhongshan Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03966209"
137,"NCT03274479","PBF-1129 in Patients With NSCLC",,"Recruiting","No Results Available","Locally Advanced or Metastatic NSCLC","Drug: PBF-1129","Maximum Tolerated Dose (MTD) of PBF-1129|Time to PBF-1129 peak concentration in plasma ""Tmax""|Time to PBF-1129 peak concentration in plasma at steady state ""Tmax,ss""|PBF-1129 peak concentration in plasma ""Cmax""|PBF-1129 peak concentration in plasma at steady state""Cmax,ss""|The area under PBF-1129 plasma concentration-time curve to infinite time ""AUC(0-inf)""|The area under PBF-1129 plasma concentration-time curve up to time 't' ""AUC(0-t)""|The area under PBF-1129 plasma concentration-time curve over the dosing interval ""AUC(0-τ)""|PBF-1129 half-life in plasma "" t½""|Efficacy as measured by Objective response rate (ORR)|Efficacy as measured by Disease control rate (DCR)|Efficacy as measured by duration of response (DoR)|Efficacy as measured by progression-free survival (PFS)|Efficacy as measured by overall survival (OS)","Palobiofarma SL|Ohio State University","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PBF-1129CT_03","October 1, 2018","November 1, 2019","December 31, 2019","September 7, 2017",,"November 6, 2018","Division of medical Oncology A450B Starling Loving Hall, Ohio City, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03274479"
138,"NCT02574533","Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma",,"Completed","No Results Available","Melanoma Recurrent|Malignant Melanoma|Melanoma","Biological: Vigil|Drug: Pembrolizumab","Tumor Immune-Related Response to Vigil and Vigil + Pembrolizumab|Best Overall Response Rate (ORR) to Vigil and Vigil + Pembrolizumab|Toxicities and AEs for Vigil + Pembrolizumab according to the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03","Gradalis, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CL-PTL-123","October 2015","September 2017","September 2017","October 14, 2015",,"September 27, 2017","Texas Oncology P.A., Texas Cancer Center, Abilene, Texas, United States|Mary Crowley Medical Research Centers, Dallas, Texas, United States|Cancer Care Northwest, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02574533"
139,"NCT03493932","Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade",,"Recruiting","No Results Available","Glioblastoma","Drug: Nivolumab|Drug: BMS-986016","Increase of interferon gamma levels|Microdialysis safety|Drug Safety","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180077|18-N-0077","September 24, 2018","June 1, 2021","June 1, 2021","April 11, 2018",,"May 27, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03493932"
140,"NCT03754179","Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma","COMBI-R2","Recruiting","No Results Available","Melanoma","Drug: Dabrafenib|Drug: Trametinib|Drug: Hydroxychloroquine","Ph. 1: incidence of adverse events of DAB, TRA and HCQ|Ph. 2 Arm A: objective response rate (ORR) of DAB, TRA and HCQ|Ph. 1: objective response rate (ORR) of DAB, TRA and HCQ|Ph. 1: progression-free survival (PFS) on DAB, TRA and HCQ|Ph. 1: overall survival (OS) on DAB, TRA and HCQ|Ph. 1: value of BRAF V600 mutant circulating tumor DNA (ctDNA) as a predictive and/or prognostic marker during treatment DAB, TRA and HCQ|Ph. 2 Arm B: objective response rate 1 (ORR 1) of DAB and TRA prior to the addition of HCQ at progression of disease|Ph. 2 Arm B: objective response rate 2 (ORR 2) of DAB and TRA following the addition of HCQ at progression of disease|Ph. 2 Arm A: progression-free survival (PFS) on DAB, TRA and HCQ|Ph. 2 Arm A: overall survival (OS) on DAB, TRA and HCQ|Ph. 2 Arm B: progression-free survival 1 (PFS 1) on DAB and TRA prior to the addition of HCQ|Ph. 2 Arm B: progression-free survival 2 (PFS 2) on DAB and TRA following the addition of HCQ|Ph. 2 Arm B: overall survival 1 (OS 1) on DAB and TRA prior to the addition of HCQ|Ph. 2 Arm B: overall survival 2 (OS 2) on DAB and TRA following the addition of HCQ|Ph. 2 Arm B: overall survival 3 (OS 3) on DAB and TRA following the addition of HCQ|Ph. 2 Arm A and B: incidence of adverse events of DAB, TRA and HCQ|Ph. 2 Arm A and B: value of BRAF V600 mutant circulating tumor DNA (ctDNA) as a predictive and/or prognostic marker during treatment with DAB, TRA and HCQ","Universitair Ziekenhuis Brussel|University Hospital, Ghent","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-BN-004","January 23, 2018","February 1, 2020","December 1, 2020","November 27, 2018",,"December 7, 2018","UZ Brussel, Jette, Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT03754179"
141,"NCT03893903","AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma","AMPLIFY-NEOVAC","Recruiting","No Results Available","Malignant Glioma","Drug: IDH1R132H peptide vaccine|Drug: Avelumab","safety and tolerability: Regime Limiting Toxicity|immunogenicity of the IDH1 peptide vaccine|Frequency of Treatment-Emergent Adverse Events (Assessment of Tolerability)|Objective response rate (ORR) to assess the efficacy of Avelumab in association with the number of non-synonymous mutations in the tumor tissue.|Overall survival (OS)|Progression-free survival (PFS)|Objective response rate (ORR)|Association between immunogenicity and Objective response rate (ORR)|Association between immunogenicity and Progression-free Survival (PFS)|Association between immunogenicity and Overall survival (OS)","German Cancer Research Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCT-2016-0458|2017-000587-15|NOA-21","October 19, 2018","August 2021","August 2022","March 28, 2019",,"March 28, 2019","Charité Berlin, Neurosurgery, Berlin, Germany|University Hospital Dresden, Neurosurgery, Dresden, Germany|Essen University Hospital, Neurooncology, Essen, Germany|University Hospital Frankfurt, Neurooncology, Frankfurt/Main, Germany|University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany|Mannheim University Hospital, Mannheim, Germany|LMU, University Hospital Munich, Munich, Germany|Katharinenhospital Stuttgart, Neurosurgery, Stuttgart, Germany|University Hospital Tuebingen, Neurooncology, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT03893903"
142,"NCT03422094","Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma",,"Active, not recruiting","No Results Available","Glioblastoma","Biological: NeoVax|Biological: Nivolumab|Biological: Ipilimumab|Procedure: Research blood draw|Procedure: Leukapheresis for research","Safety and tolerability of regimen as measured by a <= 33% dose-limiting toxicity (DLT) rate for a given cohort|Feasibility of generating a personalized neoantigen peptide vaccine as measured by the ability to identify candidate tumor-specific neoantigens|Feasibility of generating a personalized neoantigen peptide vaccine as measured by the the ability to manufacture a neoantigen-based synthetic long peptide vaccine|Feasibility of generating a personalized neoantigen peptide vaccine as measured by the ability to administer the vaccine to a patient at 4 weeks post-completion of radiotherapy|Immunogenicity of a personalized neoantigen peptide vaccine as measured by the ability to generate a measurable neoantigen-specific T cell response in vaccinated patients|Immunogenicity of a personalized neoantigen peptide vaccine as measured by the number of individual neoantigens per number of neoantigens vaccinated against, with which a measurable T cell-specific response|Number of high quality candidate neoantigens present in patients with newly diagnosed glioblastoma|Progression-free (PFS) survival rate|Overall survival (OS) rate","Washington University School of Medicine|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201804195","October 31, 2018","May 25, 2020","February 26, 2021","February 5, 2018",,"June 2, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03422094"
143,"NCT03354962","Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)",,"Recruiting","No Results Available","Melanoma","Combination Product: Nivolumab + Ipilimumab|Combination Product: Combined treatment schema","Phase I: Dose Limiting Toxicities (DLT) incidence.|Phase I: Abscopal effect.|Phase II: The primary endpoint is the rate of patients alive without progression at 6 months.|Phase I: Safety will be evaluated using NCI CTCAE V4.03 criteria.|Phase II: Progression Free Survival (PFS) is defined as the time from inclusion until progression or death.|Phase II: Safety will be evaluated using NCI CTCAE V4.03.|Phase II: Pattern of response rate will be followed in irradiated and non-irradiated lesions separately by CT-scan evaluation using RECIST V1.1.","Institut Claudius Regaud","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17 CUTA 11","October 15, 2018","September 2022","March 2024","November 28, 2017",,"August 8, 2019","Chu Bordeaux, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Eugene Marquis, Rennes, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03354962"
144,"NCT03161756","Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma","CHARLI","Recruiting","No Results Available","Melanoma Stage Iv|Melanoma Stage Iii|Melanoma","Drug: Denosumab|Drug: Nivolumab|Drug: Ipilimumab","Median Progression-Free Survival|Occurrence of Grade 3 and 4 Selected Immune-related Adverse Events (irAEs) of interest|Rate of Grade 3 and 4 irAEs|Best Overall Response According to RECIST 1.1|Progression-Free Survival|Overall Survival|Toxicity Profiles of the Checkpoint-Denosumab Combinations|Occurrence of Treatment Discontinuation Due to Toxicity","Melanoma and Skin Cancer Trials Limited|Peter MacCallum Cancer Centre, Australia|Amgen|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01.15","December 7, 2017","June 2021","June 2023","May 22, 2017",,"January 6, 2020","Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Bendigo Health, Bendigo, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03161756"
145,"NCT04047706","Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma",,"Recruiting","No Results Available","Glioblastoma","Biological: IDO1 Inhibitor BMS-986205|Biological: Nivolumab|Radiation: Radiation Therapy|Drug: Temozolomide","Incidence of adverse events (AEs)|Overall survival|Median survival|Progression free survival at 6 months|Median time to disease progression|Radiographic response rates (RR)|Response rate|Median duration of response","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 18C02|NCI-2019-04922|STU00209583|P30CA060553","August 13, 2019","June 9, 2022","June 1, 2023","August 7, 2019",,"June 4, 2020","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04047706"
146,"NCT03384836","Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery",,"Recruiting","No Results Available","Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Propranolol Hydrochloride","Dose limiting toxicities (DLT) defined as any grade 3 or higher hematological or non-hematological toxicity that is probably or definitely related to treatment according to Common Terminology Criteria for Adverse Events version 4.03 (Phase Ib)|Overall response rate (ORR) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) version 1.1 (Phase II)|Overall survival (OS) (Phase II)|PFS (Phase II)|Progression free survival (PFS) (Phase II)","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","47","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 53217|NCI-2017-02210|P30CA016056","January 31, 2018","October 11, 2020","October 11, 2021","December 27, 2017",,"February 26, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States|Penn State Milton S. Hershy Medical Center Cancer Institute, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03384836"
147,"NCT02406183","Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma",,"Completed","No Results Available","Melanoma|Effects of Immunotherapy|Adverse Effect of Radiation Therapy","Radiation: Stereotactic body radiotherapy (SBRT)|Drug: Ipilimumab","Maximal tolerated dose (MDT) that is associated with dose-limiting toxicity (DLT) in 25% of patients.|Preliminary anti-tumor activity following escalating doses of radiation combined to ipilimumab using the immune related response criteria irRC|Overall survival|Progression-free survival|Immunomonitoring (absolute lymphocyte count)|Immunomonitoring (frequencies of Foxp3+ Treg-cells)|Immunomonitoring (functional analysis looking at shifts in Th1/Th2/Th17)|Immunomonitoring (plasmacytoid dendritic cells and myeloid derived suppressor cells and their IDO expression)","Radiotherapie|University Hospital, Ghent","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC 2015/0025","March 2015","August 2016","August 2016","April 2, 2015",,"January 10, 2017","Dept. of Radiotherapy, Ghent University Hospital, Ghent, Oost-Vlaanderen, Belgium",,"https://ClinicalTrials.gov/show/NCT02406183"
148,"NCT02935361","Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed",,"Recruiting","No Results Available","Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Drug: Atezolizumab|Drug: Guadecitabine","Incidence of dose-limiting toxicities evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Overall response (complete response [CR] + partial response + marrow CR + hematological improvement) (Phase II)|Incidence of grade 3 or higher adverse events and grade 2 toxicities that do not resolve after 3 weeks assessed by CTCAE 4.0|Overall response rate (Phase II)|Overall survival|Percentage of patients who were transfusion-dependent on study entry who become transfusion-independent|Progression free survival|Time to best response","University of Southern California|National Cancer Institute (NCI)|Van Andel Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9L-16-3|NCI-2016-01233|P30CA014089","November 2, 2016","November 2, 2020","November 2, 2021","October 17, 2016",,"July 8, 2019","USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02935361"
149,"NCT03522584","Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",,"Recruiting","No Results Available","Metastatic Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma","Biological: Durvalumab|Other: Laboratory Biomarker Analysis|Radiation: Stereotactic Body Radiation Therapy|Biological: Tremelimumab|Procedure: Hypofractionated Image-Guided Radiation Therapy","Incidence of adverse effects graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0|Response rate|Progression-free survival|Overall survival","University of Washington|National Cancer Institute (NCI)|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9881|NCI-2018-00540|P30CA015704|RG1717067","May 17, 2018","February 15, 2021","February 15, 2021","May 11, 2018",,"April 8, 2020","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03522584"
150,"NCT02879695","Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia",,"Recruiting","No Results Available","Recurrent B Acute Lymphoblastic Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Mixed Phenotype Acute Leukemia","Biological: Blinatumomab|Biological: Ipilimumab|Biological: Nivolumab","Incidence of adverse events|Maximum tolerated dose|Minimal residual disease|Anti-leukemia activity|Complete remission|Complete remission with incomplete blood count recovery|Progressive disease|Duration of response|Overall survival","National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1","36","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2016-01300|ETCTN10030|10030|UM1CA186691","May 5, 2017","November 5, 2021","November 5, 2021","August 26, 2016",,"June 1, 2020","Yale University, New Haven, Connecticut, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02879695"
151,"NCT04116658","First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma","ROSALIE","Not yet recruiting","No Results Available","Glioblastoma, Adult","Biological: Multiple dose of EO2401","Safety and tolerability of EO2401: National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0|Evaluation of survival|Assessment of the immunogenicity of EO2316, EO2317, EO2318 (Three components of the therapeutic vaccine), and Universal Cancer Peptide that compose EO2401","Enterome|Covance","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EOGBM1-18","July 2020","August 2023","August 2023","October 4, 2019",,"March 30, 2020","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Centre Georges François Leclerc, Dijon, France|Hôpital Pitié-Salpétrière, Paris, France|Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn, Bonn, Germany|Universitätsklinikum Frankfurt Goethe-Universität Dr. Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, Germany|Neurologische Klinik & Nationales Zentrum für Tumorenerkrankungen Heidelberg Universitätsklinikum Heidelberg, Heidelberg, Germany|Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany|Zentrum für Neuroonkologie Universitätsklinikum Tübingen, Tübingen, Germany|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institit Catala D'Oncologia - Hospital Duran i Reynals, Hospitalet De Llobregat, Spain",,"https://ClinicalTrials.gov/show/NCT04116658"
152,"NCT03605589","Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma",,"Recruiting","No Results Available","Leukemia, B-cell|Lymphoma, B-Cell","Drug: Blinatumomab|Drug: Pembrolizumab","Feasibility of combining pembrolizumab and blinatumomab (dose limiting toxicities)|Treatment related toxicities|Disease response","Children's Hospital Medical Center, Cincinnati","All","1 Year to 40 Years   (Child, Adult)","Phase 1","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pembro-EB-1701","September 27, 2018","August 2021","January 2022","July 30, 2018",,"June 4, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03605589"
153,"NCT02557321","PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma",,"Recruiting","No Results Available","Melanoma","Drug: PV-10|Drug: Pembrolizumab","Safety and tolerability of the combination regimen assessed by adverse events (AEs)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Change in immune biomarkers|Overall Survival (OS)","Provectus Biopharmaceuticals, Inc.|Provectus Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","192","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PV-10-MM-1201","October 2015","April 2021","November 2023","September 23, 2015",,"March 5, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Oregon Health & Science University, Portland, Oregon, United States|St Luke's University Health Network, Easton, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Princess Alexandra Hospital, Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT02557321"
154,"NCT02535078","Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma",,"Recruiting","No Results Available","Malignant Melanoma","Drug: IMCgp100|Drug: durvalumab|Drug: tremelimumab","Progression-free survival|Objective response rate|Overall survival","Immunocore Ltd|MedImmune LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMCgp100-201","November 2015","May 2022","August 2022","August 28, 2015",,"April 21, 2020","The Angeles Clinic and Research Institute, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Cancer Center, Durham, North Carolina, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Tenessee Oncology, Nashville, Tennessee, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Herlev og Gentofte Hospital, Herlev, Denmark|Universitaetsklinikum Heidelberg, Heidelberg, Baden Wuerttemberg, Germany|Universitaetsklinikum Essen, Essen, Nordrhein Westfalen, Germany|Universitaetsklinikum Koeln, Koeln, Nordrhein Westfalen, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Sachsen, Germany|Istituto Tumori Napoli Fondazione G. Pascale, Napoli, Italy|Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|The Christie, Department of Oncology, Manchester, Greater Manchester, United Kingdom|Churchill Hospital, Oxford, Headington, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Strathclyde, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02535078"
155,"NCT02259231","RTA 408 Capsules in Patients With Melanoma - REVEAL",,"Completed","No Results Available","Melanoma|Unresectable (Stage III) Melanoma|Metastatic (Stage IV) Melanoma","Drug: Omaveloxolone Capsules (2.5 mg/capsule)|Drug: Ipilimumab (3 mg/kg)|Drug: Nivolumab (240 mg)|Drug: Omaveloxolone Capsules (10 mg/capsule)|Drug: Omaveloxolone Capsules (50 mg/capsule)","Measure of overall response rate using RECIST (Response Evaluation Criteria in Solid Tumors) of the Phase 2 dose of omaveloxolone with nivolumab","Reata Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RTA 408-C-1401","October 2014","May 9, 2018","July 23, 2018","October 8, 2014",,"May 9, 2019","Southern Cancer Center, Mobile, Alabama, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|University of Colorado Cancer Center, Anschutz Cancer Pavilion, Aurora, Colorado, United States|Christiana Hospital Helen F. Graham Cancer Center, Newark, Delaware, United States|Goergetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|Duke Cancer Institute, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02259231"
156,"NCT03726515","CART-EGFRvIII + Pembrolizumab in GBM",,"Active, not recruiting","No Results Available","Glioblastoma","Biological: CART-EGFRvIII T cells|Biological: Pembrolizumab","Number of subjects with treatment-related adverse events, using NCI CTCAE v5.0.|Overall survival Rate|Progression-free survival (PFS)|Objective response rate (ORR)","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","831706, UPCC 13318","March 11, 2019","December 2020","December 2034","October 31, 2018",,"March 27, 2020","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03726515"
157,"NCT03792347","Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squmous Cell Carcinoma of Esophageus","PALACE","Active, not recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: Pembrolizumab","Safety(The rates of grade 3 and higher-grade treatment-related adverse events)|Feasibility (The rates of patients who finished pembrolizumab with chemoradiotherapy and receive surgery within 6 weeks after preoperative therapies.)|Pathologic complete response|Radiographic response","Hecheng Li M.D., Ph.D|Ruijin Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RuijinH-nit","January 21, 2019","March 17, 2020","June 17, 2020","January 3, 2019",,"June 2, 2020","Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03792347"
158,"NCT03750071","VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma",,"Recruiting","No Results Available","Recurrent Glioblastoma","Biological: VXM01|Biological: Avelumab","Treatment-emerging adverse events (safety and tolerability of VXM01 in combination with avelumab)|Clinical response as assessed by time to progression (TTP)|Clinical response as assessed by progression free survival (PFS)|Clinical response as assessed by recurrence-free survival after re-operation (RFS)|Clinical response as assessed by Overall Survival (OS)|Best overall response (OR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)|Duration of Response (DoR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)","Vaximm GmbH|Merck KGaA, Darmstadt, Germany|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VXM01-AVE-04-INT","November 21, 2018","December 31, 2020","December 31, 2020","November 21, 2018",,"July 19, 2019","CHU La Timone, Marseille, France|Neurology Clinic and National Center for Tumor Diseases, Heidelberg, Germany|Neurology Clinic, Mannheim, Germany|UMC, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03750071"
159,"NCT03123276","Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma","GEMMK","Recruiting","No Results Available","Sarcoma","Drug: Pembrolizumab|Drug: Gemcitabine","Maximum tolerated dose of gemcitabine that can be safely combined with pembrolizumab in the absence of dose limiting toxicities.|Immunophenotyping of biopsies (FFPE samples, density and phenotype of tumour infiltrating lymphocytes; CD3+, CD8+, CD45, FoxP3 and PD1)|Location of tumour infiltrating lymphocytes (proximity to tumour cells and location relative to the microvasculature; Prototype analysis software at ICR)|Response stratification according to tumour PD-L1 expression|preliminary evaluation of response by using RECIST v1.1","Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CCR 4541","November 29, 2017","December 2020","December 2020","April 21, 2017",,"May 19, 2020","Royal Marsden, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03123276"
160,"NCT04021420","Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma","SONIMEL01","Not yet recruiting","No Results Available","Melanoma|Metastatic Melanoma","Device: SONOCLOUD|Drug: Nivolumab Injection","Most Successful Dose (MSD)|Best overall response rate, M3|Overall response rate, M3|Best intracranial overall response rate (BICORR), M3|Intracranial overall response rate (ICORR), M3|Best extracranial overall response rate (BECORR), M3|Extracranial overall response rate (BECORR), M3","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P160950J","July 5, 2019","January 1, 2022","July 5, 2023","July 16, 2019",,"July 16, 2019","Saint-Louis Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04021420"
